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Cholesterol is essential for the human body as it is a constituent of most membranes, is 
needed for bile acid synthesis, and is a precursor for steroid hormones and vitamin D. 
However, too much cholesterol is harmful, because it can accumulate in macrophages within 
the arterial wall and thereby contribute to the development of atherosclerosis. 
Atherosclerosis, the build-up of fatty substances in the arterial wall, is the most common 
cause of cardiovascular diseases (CVD), an umbrella term for diseases related to heart and 
blood vessels such as coronary heart disease (CHD). CHD is the consequence of disrupted 
blood flow to the heart due to fat deposits in the coronary arteries. The development of the 
so-called atherosclerotic plaque is a complex process that involves endothelial dysfunction, 
inflammation, proliferation of smooth muscle cells and connective tissue, and the 
accumulation of lipids such as cholesterol [1]. Under normal conditions, macrophages export 
their excess cholesterol, but when the balance between cholesterol influx and efflux is 
disturbed, large deposits of esterified cholesterol are formed and these macrophages 
transform into lipid-loaded foam cells [2]. Our diet, in particular dietary fat intake, can 
influence the risk of developing atherosclerosis.   
 
Dietary fat 
The macronutrients fat, protein and carbohydrates provided by our diet are necessary to fuel 
our body and to keep all organs vital. Of these, fat has the highest energy density, i.e. 9 
kilocalories per gram compared with 4 kilocalories per gram for proteins or carbohydrates. 
Besides providing energy, fats have an important role as building block of cell membranes 
and as precursor for hormones and other bioactive molecules. In addition, the vitamins A, D, 
E, and K can only be absorbed when delivered with fat. The diet provides different types of 
fat, such as cholesterol and phospholipids, but the majority of dietary fats are the 
triacylglycerols, also called triglycerides, which account for more than 95% of total dietary 
fat. These triacylglycerols consist of a glycerol backbone to which three fatty acids are 
attached as depicted in Figure 1. Triacylglycerols contain a mixture of different fatty acids, 
which differ in the amount of saturation (saturated, monounsaturated, or polyunsaturated) 
and chain length. It is generally believed that unsaturated fatty acids are healthier than 
saturated fatty acids (SFA), with the exception of monounsaturated fatty acids (MUFA) in the 
trans configuration (trans fat). This is mainly based on the negative effects of saturated and 
trans fatty acids on serum low-density lipoprotein (LDL)-cholesterol concentrations [3], since 
elevated serum LDL-cholesterol concentrations are a well-established risk factor for 
atherosclerosis [4]. LDL-cholesterol is therefore also known as the ‘bad’ cholesterol.  
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Figure 1. Schematic drawing of a triacylglycerol molecule. 
Sources and intakes of dietary fat 
Dietary fat is present in almost all foods, both from animal and plant origin. Foods always 
contain a mixture of fatty acids – both saturated and unsaturated – but animal products such 
as meat and dairy products are generally high in SFA, while plant products such as vegetable 
oils are generally high in unsaturated fatty acids. Dietary guidelines recommend to consume 
15 to 35 % of total daily energy (en%) from fat [5]. However, based on the effects on serum 
LDL-cholesterol, it is advised to keep the intake of SFA below 10 en%. In the Netherlands, the 
average intake of saturated fat is 12.6 en% [6]. The most commonly consumed SFA are 
palmitic acid (C16:0; hexadecanoic acid) and stearic acid (C18:0; octadecanoic acid), 
accounting for approximately 50 and 25% of total SFA respectively according to data from 
the Rotterdam study [7]. Thus, approximately 6% of total daily energy comes from palmitic-
acid intake and 3% from stearic-acid intake. Palmitic acid is predominantly found in meat and 
dairy products such as butter, cheese, and milk but also some vegetable oils such as palm oil 
contain a high amount of palmitic acid. Cocoa butter is for example rich in stearic acid, but 
the major daily sources of stearic-acid intake are also meat and dairy products.  
 
Absorption and transport of dietary fat 
Upon ingestion of fat, the lipid droplets first become smaller by chewing and peristaltic 
movements of the stomach. When the lipid droplets enter the small intestine, bile – 
produced by the liver from cholesterol – emulsifies the fat, meaning that it further reduces 
the droplets to very small particles and also helps to make them water soluble (hydrophilic) 
as fat is insoluble in water (hydrophobic). Then, lipases – specific lipid-directed enzymes 
produced by the pancreas – hydrolyze the triacylglycerols into free fatty acids and a 
(monoacyl)glycerol molecule. The free fatty acids and (monoacyl)glycerols spontaneously 
form a micelle together with phospholipids, bile acids, and cholesterol. These micelles are 
taken up by the intestinal cells (enterocytes). Because fat is hydrophobic, it needs to be 
transported through the blood via so called lipoproteins (Figure 2). Our body can produce 
different types of lipoproteins. Upon intake of dietary fat, enterocytes produce chylomicrons, 
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which are a specific type of lipoprotein that can be recognized due to their apolipoprotein 
(apo) B48. Enterocytes secrete the chylomicrons into the lymph and these chylomicrons 
eventually end-up in the blood stream to transport the dietary fats through the rest of the 
body [8].  
 
  
Figure 2. Schematic overview of a lipoprotein. Obtained from Servier Medical Art 
(https://smart.servier.com). 
 
 
Lipoprotein metabolism 
Besides chylomicrons, also other lipoproteins are produced by the body that transport 
triacylglycerols and cholesterol molecules through the circulation. Lipoproteins are 
heterogenic particles that differ in size and composition. In general, a lipoprotein consists of 
a hydrophobic core containing cholesteryl esters and triacylglycerols, and an (partly) 
hydrophilic outer surface consisting of phospholipids, apolipoproteins, and free cholesterol 
(Figure 2). Lipoproteins are generally classified as chylomicrons, very-low density lipoproteins 
(VLDL), low-density lipoproteins (LDL), or high-density lipoproteins (HDL). The different 
lipoproteins have different functions. Chylomicrons and VLDL particles predominantly deliver 
triacylglycerols to the tissues, while LDL and HDL particles are more important for cholesterol 
transport. As mentioned before, chylomicrons are produced in the intestine by enterocytes 
and transport dietary lipids. In the circulation, the enzyme lipoprotein lipase (LPL) hydrolyses 
the triacylglycerols present in the chylomicrons which results in the delivery of fatty acids to 
different tissues such as the heart and muscles. Upon hydrolysis by LPL, the size of the 
chylomicron reduces and eventually a so-called remnant, which has now become relatively 
cholesterol-rich, is left. Chylomicron remnants can be taken-up by the liver. In the liver, VLDL 
particles are produced by hepatocytes. Like chylomicrons, VLDL particles are large particles 
rich in triacylglycerols (triacylglycerol-rich lipoproteins; TRLs) that deliver fatty acids to tissues 
via the action of LPL. In the circulation, VLDL particles become smaller due to hydrolysis and 
can either be taken up by the liver via the LDL-receptor or remain in the circulation as LDL, 
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which in turn can be endocytosed by various cells to donate cholesterol. Hepatocytes and 
enterocytes also produce apolipoprotein A-I (apoA-I) molecules that can bind to 
phospholipids and form pre-β-HDL particles. In the circulation, these pre-β-HDL particles 
become enriched with cholesterol, which is converted into cholesteryl esters by lecithin-
cholesterol acyltransferase (LCAT) for efficient storage within the lipoprotein, and eventually 
form a mature HDL particle. HDL particles can take-up cholesterol from the periphery and 
return it to the liver. This will result in either the removal of cholesterol from the body via 
excretion in bile or conversion into bile acids, or the cholesterol can re-enter the circulation 
via production of VLDL. This process is called reverse cholesterol transport. HDL particles can 
deliver cholesteryl esters directly to the liver via interaction with the scavenger receptor class 
B member 1 (SR-B1) or indirectly via cholesterol transfer to VLDL and LDL. Indirect reverse 
cholesterol transport is mediated by cholesteryl ester transport protein (CETP). CETP 
exchanges cholesteryl esters from HDL particles to VLDL and LDL particles, and 
triacylglycerols from VLDL and LDL particles to HDL particles. In this way, the VLDL and LDL 
particles get enriched with cholesterol. In addition, the triacylglycerols now present in HDL 
can be hydrolyzed by hepatic lipase and the remaining cholesterol-depleted HDL particles 
(HDL3 particles) can accept cholesterol from the periphery again [8].  
 
HDL-mediated cholesterol efflux capacity 
Many epidemiological studies have shown an inverse relationship between concentrations 
of HDL-cholesterol and CVD [9]. Therefore, HDL-cholesterol is considered as ‘good 
cholesterol’. However, this inverse relationship has recently been debated, because 
pharmacological studies that increased HDL-cholesterol concentrations with CETP-targeted 
drugs have failed to reduce cardiovascular events [10-12]. Thus, the relationship between HDL-
cholesterol and CVD does not seem to be causal and the focus has shifted more towards the 
functionality of HDL particles. HDL particles have multiple anti-atherogenic functions, among 
which the ability to accept cholesterol from the periphery via cholesterol efflux (cholesterol 
efflux capacity; CEC). HDL-mediated cholesterol efflux is the first step of – and thus crucial 
for – the reverse cholesterol transport pathway. In general, cholesterol efflux is the 
movement of cholesterol from a peripheral cell (cholesterol donor) to a cholesterol acceptor. 
Related to atherosclerosis, HDL-mediated cholesterol efflux from lipid-loaded macrophages 
– for example present in the arterial wall – is particularly important. Macrophages can 
transfer cholesterol via four different pathways, including a) passive aqueous diffusion; b) 
passive diffusion mediated by SR-B1; c) active transport mediated by ATP-binding cassette 
transporter (ABC) A1; or d) active transport mediated by ABCG1 [13]. In lipid-loaded 
macrophages, the predominant pathway is ABCA1-mediated cholesterol efflux [14]. ApoA-I 
interacts with the ABCA1-receptor and this interaction results in the efflux of cholesterol and 
some phospholipids from macrophages to lipid-poor apoA-I (pre-β-HDL) [15]. ABCA1-
mediated cholesterol efflux is inversely associated with atherosclerosis [16] and cardiovascular 
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events [17, 18]. This inverse relationship has also been demonstrated independently of 
concentrations of HDL-cholesterol and apoA-I [18]. Therefore, it appears that improving HDL 
functionality and specifically HDL-mediated cholesterol efflux via ABCA1 is a better target for 
decreasing CVD risk than simply increasing HDL-cholesterol.  
 
A schematic overview of the lipoprotein metabolism including cholesterol efflux is shown in 
the figure below (Figure 3).  
 
 
 
Figure 3. Schematic overview of lipoprotein metabolism and the reverse cholesterol transport pathway 
including cholesterol efflux from macrophages to pre-ß-HDL. Figure was created using Servier Medical 
Art (https://smart.servier.com). Abbreviations: apo, apolipoprotein; ABCA1, ATP-binding cassette 
transporter A1; CE, cholesteryl ester; CETP, cholesteryl ester transfer protein; CM, chylomicron; FC, 
free cholesterol; HDL, high-density lipoprotein; LCAT, lecithin-cholesterol acyltransferase; LDL-R, low-
density lipoprotein receptor; LPL, lipoprotein lipase; SR-B1, scavenger receptor class B member 1; TAG, 
triacylglycerol; VLDL, very-low density lipoprotein. 
 
  
HDL
Pre-β-HDL
(V)LDL
TAGCE
CETP
SR-B1
LDL-R
M
ac
ro
ph
ag
es
 
(li
pi
d-
lo
ad
en
)
ApoA1
Li
ve
r
In
te
st
in
e
Periphery
LP
L
CM
CM
 re
m
na
nt
ABCA1
FC
CHAPTER 1  General introduction 
 13 
Effects of dietary fat on lipoprotein metabolism and cholesterol efflux 
Dietary fat is known to affect serum cholesterol levels. Saturated and trans fatty acids are 
considered cholesterol-raising as compared with an iso-energetic amount of carbohydrates, 
while cis-unsaturated fatty acids are cholesterol-lowering [3]. However, not all SFA are equally 
cholesterol-raising. An exception is stearic acid (C18:0), which seems to have a neutral effect 
on serum cholesterol levels. Multiple studies have shown that palmitic acid (C16:0) raises 
serum concentrations of LDL-cholesterol and HDL-cholesterol compared with stearic acid [19]. 
The reason for this difference is still not completely understood. It has been suggested that 
the absorption of stearic acid is less than palmitic acid. Indeed, Baer and colleagues showed 
that 94% of stearic acid was absorbed versus 97% of palmitic acid. However, this difference 
is too small to explain the different effects on lipoprotein metabolism [20]. Another 
explanation may be the higher conversion of stearic acid into oleic acid (C18:1), thereby 
mimicking the effects of MUFA. However, only a small part – approximately 10% [21, 22] – of 
stearic acid is converted, which also makes it unlikely that this explains the metabolic 
differences between palmitic acid and stearic acid. Besides these minor differences in 
absorption and conversion, it is also possible that palmitic acid and stearic acid differently 
affect cellular cholesterol levels. Cellular cholesterol levels are tightly regulated via 
endogenous cholesterol synthesis and cholesterol absorption via the LDL-receptor. It has 
been shown that MUFA and polyunsaturated fatty acids (PUFA) increase the expression of 
the LDL-receptor compared with SFA, thereby enhancing clearance of both VLDL and LDL 
particles and decreasing cholesterol levels in the circulation [23]. The chain length of SFA has 
also been positively associated with the expression of the LDL-receptor, meaning that stearic 
acid upregulates the LDL-receptor compared with palmitic acid. However, this has only been 
shown in in vitro studies and in animal studies, but not in humans [23]. Why HDL-cholesterol 
concentrations are lower on a stearic acid-rich diet compared with a palmitic acid-rich diet is 
not entirely clear yet, but there are indications that CETP plays a role [24-26]. Another possible 
route is via decreased cholesterol efflux from macrophages to HDL particles resulting in lower 
HDL-cholesterol. However, if and how dietary fatty acids affect HDL-mediated cholesterol 
efflux is not yet fully understood and results are contradictive [27-30]. Since palmitic and stearic 
acids are predominant in the Western diet and have different effects on HDL-cholesterol, it 
is interesting to study their effects on HDL-mediated cholesterol efflux via ABCA1. 
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Postprandial metabolism and effects of dietary fat 
As most people consume multiple meals a day, we spend most of our daily life in a 
postprandial state. It is therefore important that we thoroughly understand postprandial 
changes and subsequent effects on cardiometabolic health.  
 
Postprandial lipemia 
Elevated and prolonged postprandial lipemia – as indicated by increased serum 
triacylglycerol concentrations – is associated with an increased risk of the development of 
CHD [31]. After intake of a single, fat-containing meal, triacylglycerol concentrations (which 
are mainly present in chylomicrons) normally peak after 3 to 5 hours and the duration of 
postprandial lipemia is about 6 to 8 hours in healthy people [32]. The peak concentration of 
triacylglycerols as well as the duration of lipemia depends on the amount and type of fat 
present in the meal. It has been shown that more than 15 grams of fat is needed to induce a 
triacylglycerol response and that intakes of 30, 40 or 50 grams of fat result in a stepwise 
increase in postprandial lipemia [33]. In addition, the intake of multiple fat-containing meals 
enhances lipemia [34]. Since people generally consume multiple meals a day, it is of interest 
to examine consecutive meal challenges to more closely mimic daily-life. Fatty-acid 
composition of the meal has less clear effects on triacylglycerol responses, but there are 
indications that SFA and MUFA have comparable effects on postprandial triacylglycerol 
concentrations, while n-6 and n-3 PUFAs tend to lower lipemia as compared to other fatty 
acids [35, 36]. In addition, the number and type of chylomicrons carrying the triacylglycerols 
(e.g. chylomicron size and/or apolipoprotein content) seems to depend on the fatty-acid 
composition of the meal [36], which shows the complexity of postprandial lipid metabolism. 
In addition, the physical characteristics of a fat – in particular the amount of solid fat at 37°C 
–  affect postprandial lipid response independent of the fatty-acid composition [37]. Lastly, 
postprandial lipemia is also influenced by many factors related to the individual, such as age, 
gender, obesity, type 2 diabetes, and genetics [31]. Increasing age is associated with higher 
postprandial triacylglycerol concentrations and women generally have lower postprandial 
lipemia than men. In addition, postmenopausal women have higher postprandial 
triacylglycerol concentrations than premenopausal women. Under pathological conditions – 
both of metabolic and genetic origin – such as obesity, type 2 diabetes or familial 
hypercholesterolemia, peak concentrations can be 2 to 3 times higher and the duration of 
lipemia can be prolonged up to 10 to 12 hours after meal in take [31, 32].  
 
Postprandial glycemia 
Postprandial glycemia – increased plasma glucose concentrations after consumption of a 
meal – is also associated with CVD [38]. In contrast to triacylglycerol concentrations, glucose 
concentrations rise quickly after meal intake and generally peak within the first hour. For 
example, in healthy young adults without overweight, the average time for glucose 
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concentrations to peak was between 46 to 50 minutes after multiple meal intakes during the 
day [39]. How long glucose concentrations remain elevated also depends on the sensitivity of 
the individual to insulin. Postprandial hyperglycemia means that glucose peak concentrations 
are elevated, which can for example be assessed by a glucose tolerance test, i.e. glucose 
concentrations ≥ 7.8 mmol/L 2 hours after intake of 75 grams of glucose [40]. In 1981, Jenkins 
et al. introduced the glycemic index which classifies a food based on its effect on postprandial 
glucose concentrations [41]. Besides the amount and type of carbohydrates, also the presence 
of fat and protein in a meal affects the glycemic index and thus postprandial glycemia [42, 43]. 
Consuming fat and/or protein together with carbohydrates lowers postprandial glycemia by 
slowing down gastric emptying or by increasing insulin secretion. Exact mechanisms are 
however not yet fully understood, and the effects of fat and protein are likely mediated via 
different mechanisms. Not much is known about effects of different dietary fatty acids on 
postprandial glucose metabolism, but one study has reported that meals rich in MUFA or 
PUFAs lower postprandial glycemia compared with meals rich in SFA [44]. Like for postprandial 
lipemia, also factors related to the individual affect postprandial glucose concentrations such 
as BMI and age. Postprandial glucose concentrations are for example higher in subjects with 
obesity (BMI ≥ 30 kg/m2) compared with subjects with a healthy-weight (BMI < 25 kg/m2) [45]. 
Also increasing age is associated with higher postprandial glycemia [46]. Besides, the so-called 
2nd meal effect is a well-known phenomenon for postprandial glucose responses, i.e. the 
response after a second meal depends on the composition of the first meal [47]. For instance, 
a breakfast with a low glycemic index lowers postprandial glycemia after lunch compared 
with a breakfast with a high glycemic index [48] and this second-meal effect can even last 
overnight, i.e. the glycemic index of a dinner affects the glucose response after breakfast the 
following morning [49].  
 
Postprandial HDL-mediated cholesterol efflux capacity 
In addition to lipemia and glycemia, postprandial HDL-mediated cholesterol efflux may also 
be important with respect to atherosclerosis. Not much is known yet about effects of 
different macronutrients on postprandial CEC, but it has been shown that consumption of a 
high-fat meal increased CEC up to 8 hours after meal intake compared to fasting 
concentrations [50-53]. If carbohydrates and proteins also affect postprandial cholesterol efflux 
is currently unknown. Moreover, the mechanism underlying postprandial changes in CEC 
after a high-fat meal is not well understood. Possibly, postprandial lipemia influences HDL 
functionality via modifying particle characteristics [51]. By comparing the effects of the 
different macronutrients on postprandial HDL-mediated cholesterol efflux, we get more 
insight in underlying mechanisms, i.e. if changes in postprandial HDL-mediated CEC are 
related to changes in triacylglycerols (induced by a high-fat meal), glucose and insulin (high-
carbohydrate meal), or insulin (high-protein meal). In addition, postprandial changes in the 
metabolism of apoA-I – the protein on HDL particles responsible for ABCA1-mediated 
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cholesterol efflux – may be related to changes in postprandial HDL-mediated cholesterol 
efflux.  
Recommended intakes of dietary fatty acids are mainly based on their effects on 
fasted serum LDL-cholesterol concentrations, even though evidence for a role of 
postprandial metabolism on CHD-risk is growing. If palmitic acid and stearic acid differently 
affect postprandial lipemia, glycemia, and HDL-mediated cholesterol efflux is not clear.    
 
This dissertation 
The aim of this dissertation was to study effects of dietary fat – predominantly the different 
saturated fatty acids palmitic acid and stearic acid –, carbohydrates, and proteins on fasting 
and postprandial HDL-mediated cholesterol efflux via the ABCA1-pathway and on other 
markers relevant for cardiometabolic diseases. For this, we have reviewed the existing 
literature on effects of palmitic acid and stearic acid on cardiometabolic risk markers in 
chapter 2. In addition, a human intervention study has been performed in which we have 
examined longer-term and postprandial effects of palmitic-acid versus stearic-acid intakes 
on HDL-mediated cholesterol efflux via ABCA1 as well as other cardiometabolic risk markers. 
Results of this study on fasting cardiometabolic risk markers are reported in chapter 3, results 
on postprandial lipemia and glycemia in chapter 4, and results on fasting lipoprotein 
subfractions as well as fasting and postprandial cholesterol efflux and secretion of apoA-I in 
chapter 5. Lastly, we have studied in humans the effects on postprandial HDL-mediated 
cholesterol efflux via ABCA1 and secretion of apoA-I after acute intakes of fats, 
carbohydrates, or proteins, and results are reported in chapter 6.   
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Abstract 
 
Background: Fats rich in palmitic or stearic acids can be interesterified to increase their 
applicability for the production of certain foods. Compared with palmitic acid, stearic acid 
lowers low-density lipoprotein (LDL)-cholesterol, a well-known risk factor for coronary heart 
disease (CHD), but effects on other cardiometabolic risk markers have been studied less 
extensively. In addition, the positional distribution of these two fatty acids within the 
triacylglycerol molecule may affect their metabolic effects.  
 
Objective: The objective was to compare the longer-term and postprandial effects of 
(interesterified) fats rich in either palmitic or stearic acids on cardiometabolic risk markers in 
humans. 
 
Methods: Two searches in PubMed/Medline, Embase (OVID) and Cochrane Library were 
performed; one to identify articles that studied effects of the position of palmitic or stearic 
acids within the triacylglycerol molecule, and one to identify articles that compared side-by-
side effects of palmitic acid with those of stearic acid. 
 
Results and Conclusions: Interesterification of palmitic acid- or stearic acid-rich fats does not 
seem to affect fasting serum lipids and (apo)lipoproteins. However, substituting palmitic acid 
with stearic acid lowers LDL-cholesterol concentrations. Postprandial lipemia is attenuated if 
the solid fat content of a fat blend at body temperature is increased. How (interesterification 
of) palmitic or stearic acid-rich fats affects other cardiometabolic risk markers needs further 
investigation.   
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Introduction 
During the last decades, many studies have been carried out to gain more insight into the 
effects of dietary fat intake on risk markers for cardiovascular disease (CVD) such as 
disturbances in lipid metabolism, glucose-insulin homeostasis, the haemostatic system, or 
low-grade systemic inflammation. A well-accepted risk factor for coronary heart disease 
(CHD) is low-density lipoprotein (LDL)-cholesterol (LDL-C), which is increased by diets rich in 
saturated and trans fatty acids. Guidelines to prevent CHD are therefore focused on the 
exchange of dietary saturated and trans fats for unsaturated fats [1]. Saturated fat, however, 
is a collective term for different saturated fatty acids that exert different metabolic effects. 
In the Western diet, palmitic acid (C16:0) and stearic acid (C18:0) are the most commonly 
consumed saturated fatty acids [2]. It is generally believed that palmitic acid is more 
cholesterol-raising than stearic acid [3, 4]. However, the effects of palmitic and stearic acids on 
other cardiometabolic risk markers are less well established. Besides chain length of 
saturated fatty acids, also the positional distribution of fatty acids within the triacylglycerol 
(TAG) molecule may be important for their metabolic effects [5]. TAG molecules consist of a 
glycerol backbone to which three fatty acids are esterified. The positional distribution of 
these fatty acids within the TAG molecule, the so-called TAG structure, can be specified by 
stereospecific numbering (sn) as sn-1, sn-2, and sn-3. With interesterification, a chemical or 
enzymatic process used by the food industry, fatty acid positions can be exchanged within 
and between TAG molecules, thereby creating new TAG structures. This structure 
determines the physical properties of a fat including its melting behavior which in turn 
determines the suitability of the fat for the food industry; solid fats are for instance more 
suitable for baked goods and certain types of margarines than oils. Some vegetable oils such 
as palm oil contain relatively high amounts of palmitic and/or stearic acid predominantly at 
the outer sn-1 and -3 positions [6]. Interesterification of these oils increases the amounts of 
palmitic or stearic acids at sn-2, which will increase their melting points. Since no trans fatty 
acids are generated by interesterification, this process seems to be a good alternative for 
partially hydrogenated trans fats. However, the positional distribution of fatty acids may 
affect their metabolic fate, also because the dietary fatty acid at the sn-2 position is largely 
retained when incorporated into chylomicron TAG molecules [7]. Given that fats rich in 
palmitic and/or stearic acid are often used for interesterification, it is important that we 
thoroughly understand their impact on metabolic health. We have therefore systematically 
reviewed the current knowledge on the longer-term and postprandial effects on 
cardiometabolic risk markers of 1) the effect of interesterification of either palmitic acid- or 
stearic acid-rich fats and 2) the difference between palmitic acid- and stearic acid-rich fats.  
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Methods 
The databases PubMed/Medline, Embase (OVID) and Cochrane Library were searched for 
papers published until December 2019. Two searches were performed; one to identify 
articles that studied effects of the position of palmitic acid or stearic acid on the TAG 
molecule, and one to identify articles that compared side-by-side effects of palmitic acid with 
those of stearic acid. For the effect of TAG structure, the following search strategies were 
used: ((interesterified[All Fields] OR "esterification"[MeSH Terms] OR "TAG structures"[All 
Fields] OR "triglycerides/administration and dosage"[MeSH Terms]) AND ("palmitic acid"[All 
Fields] OR "stearic acid"[All Fields])) for PubMed, ((triglyceride structure/ OR *triacylglycerol/ 
OR interesterification.mp.) AND (stearic acid/ OR palmitic acid/)) with ‘article’ as filter for 
Embase, and ((esterification [MeSH descriptor] OR triglycerides [MeSH descriptor with 
qualifier administration and dosage] OR TAG structures OR interesterified) AND (palmitic acid 
OR stearic acid)) in Cochrane Library. For the comparison of palmitic acid with stearic acid, 
the following search strategies were used: (("palmitic acid"[All Fields] OR "palmitate"[All 
Fields] OR "hexadecanoic acid"[All Fields] OR "C16:0"[All Fields]) AND ("stearic acid"[All 
Fields] OR "octadecanoic acid"[All Fields] OR "stearate"[All Fields] OR "C18:0"[All Fields])) 
AND "clinical study"[Publication Type] for Pubmed, (*palmitic acid/ and *stearic acid/ and 
human.mp) for Embase, and (palmitic acid AND stearic acid) for Cochrane Library.  
 
Studies were eligible if they met the following inclusion criteria: human dietary intervention 
trial comparing diets or meals containing either palmitic or stearic acid mainly at sn-1 and -3 
with diets or meals containing higher amounts of palmitic or stearic acid at the sn-2 position 
or comparing diets or meals rich in palmitic acid with diets or meals rich in stearic acid; diets 
or meals had comparable contents of saturated fatty acids (SFAs), monounsaturated fatty 
acids (MUFAs) and polyunsaturated fatty acids (PUFAs); subjects were ≥ 18 years and 
apparently healthy; cardiometabolic risk markers (lipids and lipoproteins, hematological 
markers, glucose-insulin homeostasis, endothelial function markers, and/or inflammation 
markers) were assessed; articles were published in English and available as full text.   
The search for the effect of the position of either palmitic or stearic acid within the TAG 
molecule resulted in a total of 932 records (248 from PubMed, 646 from Embase, 38 from 
Cochrane) of which 100 records were duplicates. Twenty-six records from the remaining 832 
were considered to be of interest based on their titles and abstracts. After screening of the 
full texts, two articles were excluded because the fatty-acid contents of the experimental fats 
were not comparable, one because no cardiometabolic risk markers were assessed, one 
because subjects had type 2 diabetes, and five because they were conference abstracts. 
Reference lists of all eligible papers were searched for additional studies, which resulted in 
another three articles. In the end, a total of 20 articles corresponding to 19 human 
intervention trials were included (Supplemental Figure 1). 
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The search for palmitic acid versus stearic acid resulted in a total of 372 records (111 from 
PubMed/Medline, 125 from Embase and 136 from Cochrane) of which 97 records were 
duplicates. Twenty-four records from the remaining 275 were considered to be of interest 
based on their titles and abstracts. After screening of the full texts, two articles were 
excluded because experimental fats differed not only in palmitic acid and stearic acid 
contents but also in other fatty acids and four other articles because they were conference 
abstracts. Reference lists of all eligible papers and previous reviews were searched for 
additional studies, which resulted in another four articles. In the end, a total of 22 articles 
corresponding to 17 human trials were included (Supplemental Figure 2).  
 
Results 
 
Longer-term effects of sn-2 content of palmitic acid or stearic acid on fasting cardiometabolic 
risk markers 
Six studies have compared side-by-side the effects on fasting cardiometabolic risk markers 
of diets with high versus low proportions of palmitic acid at the sn-2 position (Supplemental 
Table 1) and two studies with high versus low proportions of stearic acid at sn-2 
(Supplemental Table 2). Results are summarized in Table 1. In seven studies, the content of 
palmitic or stearic acid at sn-2 was increased by interesterification of the experimental fats, 
while in one study interesterification decreased the sn-2 content of palmitic acid [8]. Studies 
examining palmitic acid-rich fats used palm oil [9, 10], palm olein [11, 12], butter [8], or a blend 
consisting mainly of coconut and palm oil [13]. Two studies have reported the solid fat content 
at 37°C; in one study both the native and interesterified palm oils were liquid [9], while in the 
other study interesterification increased the solid fat content of palm olein from 0 to 6% [11]. 
Sources for the stearic acid-rich fats were shea butter [14] and cocoa butter [15]. 
Interesterification of shea butter increased the solid fat content at 37°C from 22 to 41% [14]. 
The melting points of native and interesterified cocoa butter were not measured, but the 
authors indicated that native cocoa butter was liquid at 37°C and assumed that the solid fat 
content of the interesterified fat at 40.5°C was 19% [15]. Most studies had used a randomized 
cross-over design, except for two studies that used a parallel design [8, 12]. Experimental 
periods varied from 21 to 56 days for studies examining palmitic acid-rich fats and diets 
provided 1 to 11 energy percent (en%) of palmitic acid. The proportion of palmitic acids at 
sn-2 was reported in five out of seven studies and differed between 11 and 60% of total fatty 
acids. The two studies examining stearic acid-rich fats had interventions periods of 18 and 21 
days, and diets provided 10 and 7 en% stearic acid. One study reported proportions of stearic 
acid at sn-2, and the difference between diets was approximately 20%.  
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Lipids and (apo)lipoproteins 
Interesterification of palmitic acid-rich fats did not affect concentrations of TAG, total 
cholesterol (TC), LDL-C, or high-density lipoprotein (HDL)-C [8-13]. However, one study 
reported that men - but not women - showed a small, but statistically significant increase in 
TC and LDL-C concentrations in response to the diet with a higher sn-2 content of palmitic 
acid [9]. No differences were found for non-esterified fatty acid (NEFA) [13], apolipoprotein 
(apo)B [8, 12], apoA1 [8, 11, 12], and lipoprotein[a] concentrations [11-13]. The sn-2 content of 
stearic acid also had no effects on concentrations of TAG [14, 15], TC [14, 15], LDL-C, or HDL-C [14]. 
 
Hematological markers 
Only two studies have examined the effects of interesterification on hematological markers. 
No effects were found of sn-2 content of palmitic acid on concentrations of activated form 
of coagulation factor VII (FVIIa), fibrinogen, plasminogen activator inhibitor (PAI)-1 antigen, 
tissue plasminogen activator (tPA) antigen and its activity, and von Willebrand factor (vWF) 
[13], and of stearic acid sn-2 content on FVIIa concentrations [14].  
 
Other markers 
The proportion of palmitic acids at sn-2 did not affect concentrations of glucose [11-13], insulin 
[11, 12], C-peptide [11, 12], and C-reactive protein (CRP) [13]. Stearic acid sn-2 content also did not 
affect glucose and insulin concentrations [14].  
 
Longer-term effects of substituting palmitic acid with stearic acid on fasting cardiometabolic 
risk markers 
Eleven studies have compared side-by-side the effects of diets rich in palmitic acid with those 
of diets rich in stearic acid on fasting cardiometabolic risk markers (Table 2 and Supplemental 
Table 3). The palmitic acid sources used were palm oil [15-20], (interesterified) palm olein [21, 
22], a blend containing tripalmitin [23], and palm stearin [22]. For stearic acid-rich diets, cocoa 
butter [15, 19, 20, 24], hydrogenated soybean oil [16, 21], shea butter [17, 18], hydrogenated canola 
[22], a blend containing tristearin [23], and an interesterified blend containing fully 
hydrogenated soybean oil [12] were used. Except for one study [12], all studies used a 
randomized cross-over design. Experimental periods varied from 18 to 56 days and diets 
provided 4 to 18 en% from palmitic acids or stearic acids. Exchange of palmitic acids with 
stearic acids between the diets varied between 1 and 15 en%.  
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Table 1. Summary of studies examining the longer-term effects of substituting fats low in palmitic acid 
(C16:0) or stearic acid (C18:0) sn-2 contents with fats high in C16:0 or C18:0 sn-2 contents resp. 
Fasted 
 
Lipids and 
lipoproteins 
High 
vs low  
C16:0 
sn-2 
High 
vs low  
C18:0 
sn-2 
Hemato-
logical 
markers 
High 
vs low  
C16:0 
sn-2 
High 
vs low  
C18:0 
sn-2 
 
Other 
markers 
High 
vs low  
C16:0 
sn-2 
High 
vs low  
C18:0 
sn-2 
 
TAG 
0 ↓ 
6 = 
0 ↑ 
0 ↓ 
2  = 
0 ↑ 
 
FVIIa 
0 ↓ 
1  = 
0 ↑ 
0 ↓ 
1  = 
0 ↑ 
 
Glucose 
0 ↓ 
3  = 
0 ↑ 
0 ↓ 
1  = 
0 ↑ 
 
NEFA 
0 ↓ 
1  = 
0 ↑ 
 
NA 
Fibrino-
gen 
0 ↓ 
1  = 
0 ↑ 
 
NA 
 
Insulin 
0 ↓ 
2  = 
0 ↑ 
0 ↓ 
1  = 
0 ↑ 
 
TC 
0 ↓ 
6  =* 
0 ↑ 
0 ↓ 
2  = 
0 ↑ 
 
PAI-1 
0 ↓ 
1  = 
0 ↑ 
 
NA 
 
C-peptide 
0 ↓ 
2  = 
0 ↑ 
 
NA 
 
LDL-C 
0 ↓ 
6 =* 
0 ↑ 
0 ↓ 
1 = 
0 ↑ 
 
tPA 
0 ↓ 
1 = 
0 ↑ 
 
NA 
 
CRP 
0 ↓ 
1  = 
0 ↑ 
 
NA 
 
HDL-C 
0 ↓ 
6 = 
0 ↑ 
0 ↓ 
1 = 
0 ↑ 
 
vWF 
0 ↓ 
1 = 
0 ↑ 
 
NA 
   
 
ApoB 
0 ↓ 
3  = 
0 ↑ 
 
NA 
      
 
ApoA1 
0 ↓ 
3 = 
0 ↑ 
 
NA 
      
 
Lp[a] 
0 ↓ 
3  = 
0 ↑ 
 
NA 
      
Markers are significantly lower (↓), higher (↑) or not significantly different (=) after intake of fats high in C16:0 sn-2 
or C18:0 sn-2 contents compared with fats low in C16:0 sn-2 or C18:0 sn-2 contents respectively. *=In men, total 
and LDL cholesterol concentrations were slightly increased (0.10 mmol/L and 0.08 mmol/L respectively) on the diet 
with higher C16:0 sn-2 [9]. Abbreviations: apoB, apolipoprotein B; apoA1, apolipoprotein A1; CRP, C-reactive protein; 
FVIIa, activated factor VII; HDL-C, high-density lipoprotein cholesterol; Lp[a], lipoprotein [a]; LDL-C, low-density 
lipoprotein cholesterol; NEFA, non-esterified fatty acids; PAI, plasminogen activator inhibitor; TAG, triacylglycerol; 
TC, total cholesterol; tPA, tissue plasminogen activator; vWF, von Willebrand Factor.  
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Lipids and (apo)lipoproteins 
Concentrations of TAG did not differ between the diets [15-24], except in one study where TAG 
concentrations were lower after an interestified stearic acid-rich diet [12]. However, the 
majority of studies found lower TC concentrations on the stearic acid-rich diet compared 
with palmitic acid [15-20, 23]. In five of these studies, LDL-C concentrations were also decreased 
[16-18, 20, 23], and in two studies the concentration of LDL-C tended to be lower on stearic acid 
[12, 19]. Lower HDL-C concentrations on the stearic acid-rich diet were found in three studies 
[17, 19, 20], while in seven other studies no significant differences were found [12, 16, 18, 21-24]. No 
changes in concentrations of VLDL-C were reported [17, 19, 20]. Of the studies that measured 
apoB and apoA1 [12, 17, 19, 23], one observed decreased concentrations of apoB [17] and two of 
apoA1 [17, 19] on the stearic acid-rich diet. Lipoprotein[a] concentrations were were higher on 
the stearic acid-rich diet in one study [25] but no differences were observed in another study 
[12].   
 
Hematological markers  
One study found decreased factor VII coagulant activity (FVIIc) on the stearic acid-rich diet 
compared with palmitic acid [17]. However, FVIIc activities were not different between diets 
in another study [22]. Mean platelet volume (MPV) was lower in one study [22], but no 
difference was observed in another study of the same group [24]. No differences between 
diets were reported for other hematological markers [17, 20, 22, 24]. In one study, various 
inflammation markers were measured and no significant differences were observed [20]. 
 
Other markers 
Stearic acid decreased cholesteryl ester transfer protein (CETP) activity compared with 
palmitic acid in one study [19] and a similar decrease was observed in another study although 
not significant [23]. No effects on lecithin-cholesterol acyltransferase (LCAT) activity were 
observed [23]. Three studies examined effects on glucose metabolism. An intravenous glucose 
tolerance test was performed and a comparable response in glucose and insulin was 
observed on both diets [26]. No differences were observed in fasting concentrations of glucose 
[12, 20], insulin [12, 20], and C-peptide [12].   
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Table 2. Summary of studies examining the longer-term effects of substituting fats high in palmitic 
acid (C16:0) with fats high in stearic acid (C18:0). 
Fasted 
 
Lipids and 
lipoproteins 
C18:0 
vs 
C16:0 
Hemato-
logical 
markers 
C18:0 
vs 
C16:0 
 
C18:0 
vs 
C16:0 
Other 
markers 
C18:0 
vs 
C16:0 
 
TAG 
1 ↓ 
10  = 
0 ↑ 
 
FVIIc 
1 ↓ 
1  = 
0 ↑ 
Fibrino-
gen 
0 ↓ 
1  = 
0 ↑ 
 
CETP activity 
1 ↓ 
1  = 
0 ↑ 
 
TC 
7 ↓ 
4  = 
0 ↑ 
 
MPV 
 
1 ↓ 
1  = 
0 ↑ 
Plasmino-
gen 
0 ↓ 
1  = 
0 ↑ 
 
LCAT activity 
0 ↓ 
1  = 
0 ↑ 
 
VLDL-C 
0 ↓ 
4  = 
0 ↑ 
PAI-1 
activity 
 
0 ↓ 
1  = 
0 ↑ 
 
WBC 
 
0 ↓ 
2  = 
0 ↑ 
 
Glucose 
0 ↓ 
2  = 
0 ↑ 
 
LDL-C 
5 ↓ 
5  = 
0 ↑ 
PAI-1 
antigen 
 
0 ↓ 
1  = 
0 ↑ 
 
RBC 
 
0 ↓ 
2  = 
0 ↑ 
 
Insulin 
0 ↓ 
2  = 
0 ↑ 
 
HDL-C 
3 ↓ 
7  = 
0 ↑ 
tPA 
activity 
 
0 ↓ 
1  = 
0 ↑ 
 
Hb 
 
0 ↓ 
2  = 
0 ↑ 
 
C-peptide 
0 ↓ 
1  = 
0 ↑ 
 
ApoB 
1 ↓ 
4  = 
0 ↑ 
tPA 
antigen 
 
0 ↓ 
1  = 
0 ↑ 
 
PLT 
0 ↓ 
2  = 
0 ↑ 
Various 
inflammation 
markers 
0 ↓ 
1  = 
0 ↑ 
 
ApoA1 
2 ↓ 
3  = 
0 ↑ 
 
EFA 
0 ↓ 
1  = 
0 ↑ 
 
APTT 
 
0 ↓ 
1  = 
0 ↑ 
  
 
Lp[a] 
0 ↓ 
1  = 
1 ↑ 
Thrombo
modulin 
0 ↓ 
1  = 
0 ↑ 
 
ATIII 
 
0 ↓ 
1  = 
0 ↑ 
  
   
PT 
0 ↓ 
1  = 
0 ↑ 
 
PTT 
0 ↓ 
1  = 
0 ↑ 
  
Markers are significantly lower (↓), higher (↑) or not significantly different (=) after intake of fats high in C18:0 
compared with fats high in C16:0. Abbreviations: apoB, apolipoprotein B; apoA1, apolipoprotein A1; APTT, activated 
partial thromboplastin time; ATIII, antithrombin III; CETP, cholesteryl ester transfer protein; EFA, euglobulin 
fibrinolytic activity; FVIIc, Factor VII coagulant activity; HDL-C, high-density lipoprotein cholesterol; Hb, hemoglobin; 
IE, interesterified; LCAT, lecithin-cholesterol acyltransferase; Lp[a], lipoprotein [a]; LDL-C, low-density lipoprotein 
cholesterol; MPV, mean platelet volume; PAI, plasminogen activator inhibitor; PLT, platelet count; PT, prothrombin 
time; PTT, partial thromboplastin time; RBC, red blood cells; TAG, triacylglycerol; TC, total cholesterol; tPA, tissue 
plasminogen activator; VLDL, very low-density lipoprotein; WBC, white blood cells. 
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Postprandial effects of sn-2 content of palmitic acid or stearic acid on cardiometabolic risk 
markers 
Eight studies have compared side-by-side postprandial effects of meals with high versus low 
proportions of palmitic acid at the sn-2 position (Supplemental Table 4), and four studies with 
high versus low proportions of stearic acid (Supplemental Table 5). Results are summarized 
in Table 3. Most of the studies examining palmitic acid-rich meals have used palm olein. 
Interesterification of palm olein not only increased the palmitic acid content at sn-2, but also 
the solid fat content at 37°C. In one study, lard was used [27], in which interesterification 
decreased the palmitic acid at sn-2 as well as the solid fat content. Another study used a 
commonly consumed blend of palm stearin and palm kernel (PSt/PK) [28]. Interesterification 
of the PSt/PK blend increased palmitic acid at sn-2, but decreased the solid fat content at 
37°C. The stearic acid-rich meals consisted of structured TAG molecules with predominantly 
stearic and oleic acid (C18:1) [29], cocoa butter [30], shea butter [14], or canola stearin [31]. 
Interesterification of cocoa and shea butter increased the proportion of stearic acid at sn-2 
and the solid fat content at 37°C, which decreased after interesterification of canola stearin. 
For palmitic acid-rich meals, total fat content of the meals varied between 40 and 75 grams, 
of which 12 to 30 grams originated from palmitic acid. Differences between meals in the 
proportion of palmitic acids at sn-2 varied between 17.0 and 66.8% of total fatty acids at sn-
2. For stearic acid-rich meals, total fat content varied between 50 and 102 grams including 
17 to 30 grams of stearic acid. Two of the four studies reported the proportions of stearic 
acids at sn-2 and differences between meals were 19.7 and 25.0%. Postprandial follow-up 
varied between 4 and 8 hours. 
 
Lipids and (apo)lipoproteins 
A lower postprandial TAG response - as indicated by the incremental area under the curve 
(iAUC) - was observed in one study after a meal with higher palmitic acid sn-2 content [32]. 
The same tendency was found in three other studies [27, 33, 34], and in one study this was 
accompanied by a significant lower response in the first four hours after the meal with a 
higher proportion of palmitic acid at sn-2 [34]. In contrast, one study showed an increased 
TAG response after a higher palmitic acid sn-2 content [28]. Two other studies found no 
differences in TAG responses [35, 36]. Postprandial responses of NEFAs [7, 27, 32, 34-36], TC [7, 27, 33, 
34], and HDL-, LDL- [33], VLDL-, and chylomicron cholesterol [27, 32] were comparable. ApoB48 
responses were measured in one study and no effect of sn-2 palmitic acid content was 
observed [7]. For stearic acid, three studies found no changes in total TAG responses in 
healthy-weight subjects [14, 29, 31]. In one of these studies an obese group was included, in 
which the TAG response was decreased after the high sn-2 stearic acid meal [31]. In addition, 
in another study, higher sn-2 stearic acid content decreased the TAG response in healthy-
weight subjects [30]. NEFA responses were not differently affected [14, 29, 31]. In addition, 
CHAPTER 2                                                            C18:0 vs C16:0 – Systematic review 
 31 
responses of TC as well as of LDL-C and HDL-C were comparable between meals that differed 
in stearic acid sn-2 content [14, 30, 31].  
 
Hematological markers 
In one study, no effect of palmitic acid sn-2 content was observed on FVIIa responses [33]. 
Interestingly, the effects of stearic acid sn-2 content were different between fat sources, i.e. 
cocoa butter with a lower stearic acid content at sn-2 increased FVIIa postprandial compared 
with cocoa butter with a higher sn-2 content [30], while the amount of stearic acid at the sn-
2 position of shea blends had no effect on FVIIa [14].  
 
Other markers 
Postprandial glucose and insulin responses after palmitic acid-rich meals were comparable 
[27, 28, 32, 33, 35-37]. However, one study found that the peak value of insulin appeared faster after 
the meal with higher sn-2 content of palmitic acid (after 60 instead of 90 minutes) [32], while 
another study observed lower insulin concentrations 30, 90 and 120 minutes after intake of 
the high sn-2 meal which was accompanied by a tendency towards a lower total insulin 
response [33]. Furthermore, one study found lower glucose-dependent insulinotropic 
polypeptide (GIP) concentrations after the high sn-2 meal [37], while two other studies did not 
observe any differences [28, 35]. Two studies also measured peptide YY (PYY) and no significant 
differences were found [28, 37], although in one study PYY response tended to be less in women 
[37]. Only one study examined inflammatory cytokines and the endothelial function marker E-
selectin, and no differences were found [7]. Three studies examining stearic acid-rich meals 
measured postprandial glucose and insulin, and responses were comparable between the 
meals [14, 29, 31]. Furthermore, white blood count (WBC), as measured in one study, was not 
affected [14]. 
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Table 3. Summary of studies examining the postprandial effects of substituting fats low in sn-2 palmitic 
acid (C16:0) or stearic acid (C18:0) contents with fats high in sn-2 C16:0 or C18:0 contents respectively. 
Postprandial 
 
Lipids and 
lipoproteins 
High 
vs low  
C16:0 
sn-2 
High 
vs low  
C18:0 
sn-2 
Hemato-
logical 
markers 
High 
vs low  
C16:0 
sn-2 
High 
vs low  
C18:0 
sn-2 
Other 
markers 
High 
vs low  
C16:0 
sn-2 
High 
vs low  
C18:0 
sn-2 
 
TAG 
1 ↓ 
6 = 
1 ↑ 
2 ↓ 
3 = 
0 ↑ 
 
FVIIa 
0 ↓ 
1 = 
0 ↑ 
1 ↓ 
1 = 
0 ↑ 
 
Glucose 
0 ↓ 
7 = 
0 ↑ 
0 ↓ 
3 = 
0 ↑ 
 
NEFA 
0 ↓ 
6 = 
0 ↑ 
0 ↓ 
3 = 
0 ↑ 
 
WBC 
0 ↓ 
1 = 
0 ↑ 
0 ↓ 
1 = 
0 ↑ 
 
Insulin 
0 ↓ 
7 = 
0 ↑ 
0 ↓ 
3 = 
0 ↑ 
 
TC 
0 ↓ 
4 = 
0 ↑ 
0 ↓ 
3 = 
0 ↑ 
    
C-peptide 
0 ↓ 
1 = 
0 ↑ 
 
NA 
 
VLDL-C 
0 ↓ 
2 = 
0 ↑ 
 
NA 
    
GIP 
1 ↓ 
2 = 
0 ↑ 
 
NA 
 
LDL-C 
0 ↓ 
1 = 
0 ↑ 
0 ↓ 
3 = 
0 ↑ 
    
PYY 
0 ↓ 
2 = 
0 ↑ 
 
NA 
 
HDL-C 
0 ↓ 
1 = 
0 ↑ 
0 ↓ 
2 = 
0 ↑ 
    
IL-6 
0 ↓ 
1 = 
0 ↑ 
 
NA 
 
CM-C 
0 ↓ 
2 = 
0 ↑ 
 
NA 
    
IL-8 
0 ↓ 
1 = 
0 ↑ 
 
NA 
 
ApoB48 
0 ↓ 
1 = 
0 ↑ 
 
NA 
    
TNF-α 
0 ↓ 
1 = 
0 ↑ 
 
NA 
       
E-selectin 
0 ↓ 
1 = 
0 ↑ 
 
NA 
Markers are significantly lower (↓), higher (↑) or not significantly different (=) after intake of fats high in C16:0 sn-2 
or C18:0 sn-2 contents compared with fats low in C16:0 sn-2 or C18:0 sn-2 contents respectively. Abbreviations: 
apoB48, apolipoprotein B48; CM-C, chylomicron cholesterol; FVIIa, activated factor VII; GIP, glucose-dependent 
insulinotropic polypeptide; HDL-C, high-density lipoprotein cholesterol; IL, interleukin; LDL-C, low-density 
lipoprotein cholesterol; NEFA, non-esterified fatty acids; PYY, peptide YY; TAG, triacylglycerol; TC, total cholesterol; 
TNF, tumor necrosis factor; VLDL, very low-density lipoprotein; WBC, white blood cells.  
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Postprandial effects of substituting palmitic acid with stearic acid on cardiometabolic risk 
markers 
Six studies have compared side-by-side postprandial effects of meals high in palmitic acid 
with those high in stearic acid (Table 4). The fats added to enrich meals with palmitic acid 
were palm oil [38, 39], palm olein [7, 40], and a blend of tripalmitin with high-oleic sunflower oil 
(HOSO) [41]. For the stearic acid-rich meals, lard [7, 38, 40], hydrogenated HOSO [39], and a blend 
of tristearin with HOSO [41] were used. Fat content of the test meals varied between 50 and 
90 grams, from which 9 to 37 grams originated from palmitic or stearic acids. Difference 
between palmitic and stearic acid in the meals ranged between 5 and 23 en%. Postprandial 
follow-up varied between 4 and 8 hours (Supplemental Table 6).  
 
Lipids and (apo)lipoproteins 
In two studies, a lower TAG response after the meal rich in stearic acid was observed [7, 40] 
and in another study lower TAG concentration 3 hours after the stearic acid-rich meal [39]. 
Other studies did not observe any differences [38, 41, 42]. The postprandial reduction in NEFAs 
was lower after stearic-acid intake in one study [7] but no differences were observed between 
meals in two other studies [40, 41]. Postprandial responses of VLDL-C, LDL-C, HDL-C, apoB, and 
apoA1 were measured in one study, but did not differ over time and between meals [41]. Also, 
the responses in postprandial concentrations of lipoprotein[a] [43], TC and apoB48 [7] were 
not differently affected.  
 
Hematological markers 
Postprandial responses of FVIIa after a meal rich in palmitic or stearic acid were comparable 
[39, 42, 44]. However, one study observed a non-significant lower response of FVIIa 2 to 6 hours 
after the stearic acid-rich meal with relatively stable FVIIa concentrations between 4 and 8 
hours, while FVIIa peaked 6 hours after palmitic acid and then declined [44]. FVIIc responses 
were measured in two studies. In one study, no differences between the meals were found 
[39]. In the other study, however, 8 hours after the palmitic acid-rich meal FVIIc had almost 
returned to baseline, while it reached its highest value 8 hours after the stearic acid-rich 
meal. Nevertheless, no difference was found in total FVIIc response [44].  
 
Other markers 
Postprandial responses of glucose [37, 40], insulin [37, 38, 40], and C-peptide [37] were not 
differently affected. However, secretion of GIP was lower after intake of stearic acid-rich lard 
[37]. Postprandial changes in concentrations of leptin  [38, 40], inflammatory cytokines [7, 40], E-
selectin [7], and PYY [37] were comparable. In addition, changes in CETP and lipoprotein lipase 
(LPL) activity did not differ between meals [41].  
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Table 4. Summary of studies examining the postprandial effects of substituting fats high in palmitic 
acid (C16:0) with fats high in stearic acid (C18:0). 
Postprandial 
 
Lipids and 
lipoproteins 
C18:0 
vs 
C16:0 
Hemato-
logical 
markers 
C18:0 
vs 
C16:0 
Other 
markers 
C18:0 
vs 
C16:0 
 
TAG 
1 ↓ 
4 = 
0 ↑ 
 
FVIIa 
0 ↓ 
3 = 
0 ↑ 
 
Glucose 
0 ↓ 
1 = 
0 ↑ 
 
NEFA 
0 ↓ 
2 = 
0 ↑ 
 
FVIIc 
0 ↓ 
2 = 
0 ↑ 
 
Insulin 
0 ↓ 
2 = 
0 ↑ 
 
TC 
0 ↓ 
1 = 
0 ↑ 
PAI-1 
antigen 
0 ↓ 
1 = 
0 ↑ 
 
GIP 
1 ↓ 
0 = 
0 ↑ 
 
VLDL-C 
0 ↓ 
1 = 
0 ↑ 
tPA 
activity 
0 ↓ 
1 = 
0 ↑ 
 
PYY 
0 ↓ 
1 = 
0 ↑ 
 
LDL-C 
0 ↓ 
1 = 
0 ↑ 
   
Leptin 
0 ↓ 
1 = 
0 ↑ 
 
HDL-C 
0 ↓ 
1 = 
0 ↑ 
  CETP 
activity 
0 ↓ 
1 = 
0 ↑ 
 
ApoB 
0 ↓ 
1 = 
0 ↑ 
  LPL 
activity 
0 ↓ 
1 = 
0 ↑ 
 
ApoA1 
0 ↓ 
1 = 
0 ↑ 
   
IL-6 
0 ↓ 
1 = 
0 ↑ 
 
Lp[a] 
0 ↓ 
1 = 
0 ↑ 
   
TNF-α 
0 ↓ 
1 = 
0 ↑ 
     
IL-1β 
0 ↓ 
1 = 
0 ↑ 
Markers are significantly lower (↓), higher (↑) or not significantly different (=) after intake of fats high in C18:0 
compared with fats high in C16:0. Abbreviations: apoB, apolipoprotein B; apoA1, apolipoprotein A1; CETP, 
cholesteryl ester transfer protein; FVIIa, activated factor VII; FVIIc, Factor VII coagulant activity; GIP, glucose-
dependent insulinotropic polypeptide; HDL-C, high-density lipoprotein cholesterol; IL, interleukin; Lp[a], 
lipoprotein [a]; LPL, lipoprotein lipase; LDL-C, low-density lipoprotein cholesterol; NEFA, non-esterified fatty acids; 
PAI, plasminogen activator inhibitor; PYY, peptide YY; TAG, triacylglycerol; TC, total cholesterol; TNF, tumour 
necrosis factor; tPA, tissue plasminogen activator; VLDL, very low-density lipoprotein. 
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Discussion 
Interesterification is widely used by the food industry to modify TAG structures of fats to 
change their physical characteristics and thereby increase their suitability for food 
applications without the formation of trans fatty acids. The saturated fatty acids within 
interesterified fats are predominantly palmitic acid and stearic acid. To better understand 
metabolic effects of interesterified fats we have systematically reviewed effects of fats rich 
in either palmitic or stearic acid on cardiometabolic risk markers. Focus was on the position 
of palmitic acid or stearic acid within the TAG molecule and on studies that have compared 
side-by-side palmitic acid- versus stearic acid-rich fats.  
 
Longer-term effects 
Although exact intakes of interesterified fats are unknown, it has been estimated that – if all 
trans fats would be replaced with interesterified fats – the mean daily intake in the United 
States would be approximately 3 en% with an upper limit of 4.8 en% [45]. Daily intakes of 
interesterified fats as well as the proportions of total and sn-2 palmitic or stearic acids 
differed widely between studies. However, in most studies, interesterified fat intakes were 
well above the estimated upper limit of 4.8 en% [45]. Still, no effects of palmitic acid or stearic 
acid sn-2 content were found. In general, metabolically healthy and relatively young subjects 
were studied. In the only study that included mildly hypercholesterolemic subjects, also no 
effects of palmitic acid sn-2 content were observed [10]. Furthermore, studies using stearic 
acid-rich fats have been performed in men only. It is known that men and women differ in 
CVD risk [46] and may respond differently to dietary interventions [47]. Indeed, one study 
observed slightly increased TC and LDL-C in men but not in women after intake of a fat with 
a higher palmitic acid sn-2 content [9]. The difference between men and women was however 
not statistically significant, but this may be explained by lack of statistical power. Little 
research has been done on the hemostatic system, inflammation, and glucose-insulin 
homeostasis, which are all involved in the pathogenesis of CVD [48-50]. However, results so far 
do not indicate effects of diets enriched with interesterified fats on markers involved in these 
metabolic processes.    
Since the use of interesterified fats may increase stearic and/or palmitic acid intakes, we 
need to thoroughly understand their metabolic effects. Daily intakes of palmitic and stearic 
acids in the United States are approximately 6 en% and 3 en% respectively [51]. It is well known 
that stearic acid lowers concentrations of TC, LDL-C, and HDL-C as compared with palmitic 
acid [52]. Indeed, the majority of studies showed decreased TC and LDL-C concentrations on 
the stearic acid-rich diet [16-18, 23]. In three studies, lower HDL-C concentrations were observed 
[17, 19, 20]. Only one out of four studies observed a statistically significant decrease in apoB100 
concentrations on the stearic acid-rich diet [17]. However, previous meta-analyses found 
lower apoB concentrations on stearic acid compared with palmitic acid [3] and a non-
significant increase in apoB when carbohydrates were replaced with palmitic acid but not 
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when replaced with stearic acid [4]. TAG concentrations were comparable between diets, 
which may suggest that the number of VLDL particles was unchanged. It is therefore of 
interest to examine if stearic acid induces a shift towards smaller and denser LDL particles. 
Furthermore, two of the four studies found decreased apoA1 concentrations [17, 19]. It is 
uncertain if this is associated with less (pre-β) HDL particles, since one HDL particle can 
contain up to four A1 apolipoproteins [53]. As apoA1 is involved in ATP-binding cassette 
transporter (ABC) A1-mediated cholesterol efflux from peripheral cells to pre-β-HDL 
particles, it is of interest to examine if these decreased apoA1 concentrations result in 
impaired reverse cholesterol transport. Only a few studies examined effects on 
hematological markers. Platelet volume decreased when minimally 5 en% palmitic acid was 
exchanged for stearic acid [22]. Total platelet count was not affected, which suggests smaller 
platelets that are considered to be less active than larger ones [54]. In addition, FVIIc activity 
decreased when 14 en% palmitic acid was exchanged for stearic acid [17] but not when 5 en% 
was exchanged [22]. Furthermore, the first study used shea butter, while the latter used 
hydrogenated canola oil. It has been suggested that the effects of shea butter may be due to 
its non-glyceride components instead of its stearic acid content [22]. Hematological markers 
related to fibrinolysis were not affected [17, 22]. Remarkably, only one of the longer-term 
studies included in this review has addressed the effects of palmitic and stearic acids on 
inflammation [20], and only two studies examined fasting glucose and insulin concentrations 
[12, 20]. In these studies, no differences were observed, but more research is needed to confirm 
these results.  
 
Postprandial effects  
Postprandial TAG responses are highly dynamic and depend on many factors. For example 
gender, age, and obesity are known to affect postprandial lipemia [55]. Indeed, the studies 
that included obese subjects observed higher postprandial TAG responses in obese 
compared with healthy-weight subjects [31, 38]. In addition, one study observed lower 
postprandial TAG concentrations in premenopausal women than in men [7]. Normally, TAG 
concentrations in the blood peak three to five hours after the meal and return to baseline 
within six to eight hours [56]. The studies included in this review differed in postprandial 
follow-up, ranging between four and eight hours. Since not only the peak value of TAG after 
a meal, but also the time to return to fasting TAG concentrations (the duration of lipemia) is 
positively related to CVD [55, 56], it may be important to follow-up for at least six hours to gain 
more insights in both peak values and duration of lipemia. In addition, during the day, people 
generally consume another meal after four to six hours. However, none of the studies 
included a so-called second meal challenge. Introducing a second fat-rich meal four to six 
hours after the first meal has been shown to induce the release of chylomicrons that contain 
fatty acids from the previous meal [57]. Therefore, meal effects may be affected by the 
composition of the previous meal. In addition, postprandial impairment of endothelium-
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dependent vasodilation and oxidative stress are most marked after a second fat-containing 
meal [58]. Conflicting results have been reported on postprandial TAG responses of native and 
interesterified palmitic or stearic acid-rich fats. This discrepancy might be explained by the 
characteristics of the fats used, in particular the solid fat content at 37°C. In most studies, 
solid fat content increased if the proportion of palmitic acid or stearic acid at sn-2 increased. 
However, in one study solid fat content was lower for the fat blend high in palmitic acid at 
sn-2 and results of this study were opposite to those of other studies, e.g. higher TAG 
response after the fat with higher sn-2 palmitic acid content [28]. It has been suggested that 
solid fat content at body temperature rather than sn-2 palmitic or stearic acid content 
determines the postprandial TAG response [5]. It is hypothesized that a high solid fat content 
at 37°C, which is often due to tristearin (SSS) or tripalmitin (PPP) TAG species, impairs micelle 
formation [14] and reduces accessibility for pancreatic lipase [31], thereby decreasing the rate 
of absorption by the enterocyte. FVIIa responses seem to be related to postprandial lipemia, 
e.g. attenuated lipemia is associated with decreased FVIIa responses [33]. Although no 
changes in glucose and insulin responses were shown between fats differing in sn-2 palmitic 
or stearic acid content, results on postprandial release of gut hormone GIP were less clear. 
GIP induces insulin secretion and is released when fatty acids and/or carbohydrates enter 
the small intestine [59]. GIP has only been measured in studies investigating the sn-2 position 
of palmitic acid [28, 37], and results differed between these two studies. Palm oil increased GIP 
more than interesterified palm oil [37], while no difference was observed after the native and 
interesterified blend of palm stearin and palm kernel [28]. It is likely that this is due to the 
difference in physical characteristics of the control fats used; fats liquid at body temperature 
such as high oleic sunflower oil and palm oil increase GIP more than fats with solids at body 
temperature such as interesterified palm oil and lard [37]. Since both the native and 
interesterified blends of palm stearin and palm kernel were partly solid at body temperature, 
effects on GIP were possibly attenuated [28]. The only study that has measured the effects of 
positional distribution within the TAG molecules on postprandial inflammatory cytokines and 
E-selectin observed no effects of sn-2 palmitic acid content in a meal [7]. Substituting palmitic 
with stearic acid does not seem to affect postprandial responses of lipids and 
(apo)lipoproteins, although two studies observed a lower TAG response after lard compared 
with palm olein [40]. However, it is uncertain if this difference is due to the exchange between 
palmitic and stearic acid or due to differences in sn-2 content of palmitic acid and 
subsequently physical characteristics; lard has a higher solid fat content at 37°C. Postprandial 
effects on hematological markers, glucose-insulin homeostasis, and inflammation require 
further attention, but so far results do not indicate clear differences between palmitic and 
stearic acids.  
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Conclusions 
Interesterification of palmitic acid- or stearic acid-rich fats does not seem to affect fasting 
serum lipids and (apo)lipoproteins. On the other hand, stearic acid decreases LDL- and HDL-
cholesterol concentrations compared with palmitic acid. In addition, postprandial lipemia is 
attenuated if the changes in palmitic acid or stearic acid sn-2 contents increase solid fat 
content of the blend at body temperature. No evidence was found that solely substituting 
palmitic acid with stearic acid affected postprandial lipemia. However, there is need to 
further examine fasting and postprandial effects of (interesterification of) palmitic acid- and 
stearic acid-rich fats on the hemostatic system, inflammation, and glucose-insulin 
homeostasis as well as on emerging cardiometabolic risk markers such as cholesterol efflux 
capacity and lipoprotein particle size. In addition, it would be of interest for future studies to 
specifically examine populations that have a higher risk for CVD, such as elderly or people 
with obesity, and to examine sex differences as well.  
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Supplemental data 
 
 
Supplemental Figure 1. Flow chart of studies on the effects of interesterification of palmitic acid- or 
stearic acid-rich fats on cardiometabolic risk markers. Abbreviations: FA, fatty acids; CV, cardiovascular.  
 
 
Potentially relevant articles 
retrieved with the literature search 
 
N=923 
Articles excluded due to following reasons: 
• FA content not similar N=2 
• No CV risk markers assessed N=1 
• Diabetes Type II patients N=2 
• Conference abstract N=5 
Articles of interest based on title 
and abstract 
 
N=26 
Included articles 
 
N=20  
(corresponding to 19 human 
intervention trials) 
Articles excluded due to following reasons: 
• Duplicates N=100 
• No (suitable) intervention N=806 
Articles added by hand search 
 
N=3 
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Supplemental Figure 2. Flow chart of studies on the effects of palmitic acid versus stearic acid on 
cardiometabolic risk markers. Abbreviations: FA, fatty acid.  
 
 
Potentially relevant articles 
retrieved with the literature search 
 
N=372 
Articles excluded due to following reasons: 
• FA content not similar N=2 
• Conference abstract N=4 
Articles of interest based on title 
and abstract 
 
N=24 
Included articles 
 
N=22  
(corresponding to 17 human 
intervention trials) 
Articles excluded due to following reasons: 
• Duplicates N=97 
• No (suitable) intervention N=251 
Articles added by hand search 
 
N=4 
 
 
Supplemental Table 1. Longer-term effects of substituting fats low in sn-2 palmitic acid (C16:0) contents with fats high in sn-2 C16:0 contents on fasting 
cardiometabolic risk. markers. 
First author, 
Year of 
publication 
Study  
population, 
Age, 
BMI  
Duration 
intervention 
periods, 
Study design 
 
Total 
fat 
(en%)  
 
 
C16:0  
(en%) 
 
Source  
Low sn-2 
High sn-2 
C16:0  
sn-2 in fat 
blends 
(%a) 
Solid 
fat at 
37°C 
(%) 
 
 
Lipids and 
lipoproteins 
 
Hemato-
logical 
markers 
 
 
Other 
markers 
Nestel, 
1995 [10] 
27 men 
(mildly 
hyperchol$) 
49±8 y 
26.3±2.5 kg/m2 
21 days 
Crossover 
(no WO) 
31 6.7 Palm oil 
 
IE palm oil 
8.7 
24.7 
wt% 
NR TAG = 
TC = 
LDL-C = 
HDL-C =  
  
Zock, 
1995 [9] 
23 men 
37 women$$ 
29 (19-67) y 
22.9 (18.1-
30.9) kg/m2 
21 days 
Crossover 
(no WO) 
40 11 
 
Control and 
IE blend of 
palm oil 
blended with 
sunflower oil 
6.4 
66.9 
wt% 
0 
0 
TAG = 
TC =* 
LDL-C =* 
HDL-C =  
  
Meijer, 
1997 [13] 
30 men 
30 women 
±35.5 y 
±23.8 kg/m2 
21 days 
Crossover# 
(no WO) 
34 
 
1 or 
2# 
Control and 
IE blend  
(mainly 
coconut and 
palm oils 
blended with 
soybean oil) 
7.1 
18.0 
wt% 
NR TAG = 
NEFA = 
TC = 
LDL-C = 
HDL-C =  
Lp[a] = 
FVIIa =  
Fibrinogen =  
PAI-1  
antigen =  
tPA antigen = 
tPA activity =  
vWF = 
Glucose =  
CRP =  
 
Christophe, 
2000 [8] 
32 men 
23-53 y 
18.1-23.5 
kg/m2 
28 days 
Parallel 
NR 
±131g 
NR 
±5g 
IE butter 
 
Butter 
 
NR NR TAG = 
TC = 
LDL-C= 
HDL-C= 
ApoB = 
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ApoA1 =  
Filippou, 
2014 [11] 
10 men  
31 women 
±29.1 y 
±23.0 kg/m2 
42 days 
Crossover 
(no WO) 
27 9 Palm olein 
 
IE palm olein 
9.8 
45.9 
mol% 
0 
5.9 
TAG = 
TC = 
LDL-C = 
HDL-C =  
ApoB = 
ApoA1 = 
Lp[a] = 
 Glucose =  
Insulin = 
C-peptide =  
Ng, 
2018 [12] 
64 women 
21 men 
20-60y 
21-30 kg/m2 
 
 
56 days 
Parallel 
35 7 Palm olein 
 
CIE palm 
olein 
11.1 
32.4 
wt% 
NR TAG = 
TC = 
LDL-C = 
HDL-C =  
ApoB = 
ApoA1 = 
Lp[a] = 
 Glucose =  
Insulin = 
C-peptide = 
 
Markers are significantly lower (↓), higher (↑) or not significantly different (=) after intake of fats high in C16:0 sn-2 contents compared with fats low in C16:0 sn-2 contents. 
a=% of total fatty acids at sn-2. $=Subjects were mildly hypercholesterolemic (Average total cholesterol: 6.00 ± 0.78 mmol/L) [10]. $$=Pre- and postmenopausal women were 
included, however study was designed in such a way that menstrual cycle or use of oral contraceptives should not have influenced results [9]. *=In men, total and LDL cholesterol 
concentrations were slightly increased (0.10 mmol/L and 0.08 mmol/L respectively) on the diet with higher C16:0 sn-2 [9]. #=Subjects were divided into two parallel groups 
that were assigned to a diet with either 4 or 8 en% of the blends. Of the 60 subjects in total, 32 (16 men and 16 female) subjects followed the 4 en% diet (age ± 33 years, 
BMI: ± 24.1 kg/m2) and 28 (14 men and 14 female) subjects the 8 en% diet (age ± 38 years, BMI ± 23.4 kg/m2). The blends provided 1 and 2 en% palmitic acid in the 4 and 8 
en% diet respectively, total amount of palmitic acid in the diets was not reported [13]. Abbreviations: apoB, apolipoprotein B; apoA1, apolipoprotein A1; CRP, CIE, chemically 
interesterified; C-reactive protein; en%, % of total energy; FVIIa, activated factor VII; HDL-C, high-density lipoprotein cholesterol; IE, interesterified; Lp[a], lipoprotein [a]; LDL-
C, low-density lipoprotein cholesterol; NEFA, non-esterified fatty acids; NR, not reported; PAI, plasminogen activator inhibitor; sn, stereospecific numbering; TAG, 
triacylglycerol; TC, total cholesterol; tPA, tissue plasminogen activator; vWF, von Willebrand Factor; WO, wash out period; wt, weight; y, year. 
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Supplemental Table 2. Longer-term effects of substituting fats low in sn-2 stearic acid (C18:0) contents with fats high in sn-2 C18:0 contents on fasting 
cardiometabolic risk markers. 
 
First 
author, 
Year of 
publication 
 
Study  
population, 
Age, 
BMI  
Duration 
intervention 
periods, 
Study 
design 
 
 
Total 
fat 
(en%)  
 
 
 
C18:0  
(en%) 
 
 
Source  
Low sn-2 
High sn-2 
 
C18:0  
sn-2 in fat 
blends 
(%a) 
 
Solid 
fat at 
37°C 
(%) 
 
 
 
Lipids and 
lipoproteins 
 
 
Hemato-
logical 
markers 
 
 
 
Other 
markers 
Grande,  
1970 [15] 
32 men 
40-65 y 
NR 
18 days 
Latin-
square  
34 10 Native or IE 
cocoa 
butter$$ 
blended with 
safflower oil 
NR NR$ TAG = 
TC =  
  
Berry, 
2007 [14] 
16 men 
26.8±8.0 y 
23.7±3.7 
kg/m2 
21 days 
Crossover 
30g 
test 
fat#  
 
7# 
 
Native or IE 
shea butter 
blended with 
sunflower oil 
3.1 
22.8 
mol% 
22 
41 
TAG = 
TC = 
LDL-C = 
HDL-C =  
FVIIa = Glucose = 
Insulin =  
Markers are significantly lower (↓), higher (↑) or not significantly different (=) after intake of fats high in C18:0 sn-2 contents compared with fats low in C18:0 sn-2 contents. 
a=% of total fatty acids at sn-2. $=Melting points of the blends were not measured. Authors reported that native cocoa butter is normally liquid at 37°C, while they calculated 
that IE cocoa butter should have 19% solid fat content at 40.5°C [15]. $$=the interesterified cocoa butter was a mix of palm oil, totally hydrogenated soybean oil, and olive oil 
which matched the fatty acid composition of native cocoa butter [15]. #=Total daily intake of total fat and stearic acid was not reported. Diets provided 30 grams of test fat and 
an additional 7 en% (15 grams) of C18:0 per day [14]. Abbreviations: en%, % of total energy; FVIIa, activated factor VII; HDL-C, high-density lipoprotein cholesterol; IE, 
interesterified; LDL-C, low-density lipoprotein cholesterol; NR, not reported; sn, stereospecific numbering; TAG, triacylglycerol; TC, total cholesterol; y, year. 
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Supplemental Table 3. Longer-term effects of substituting fats high in palmitic acid (C16:0) with fats high in stearic acid (C18:0) on fasting 
cardiometabolic risk markers. 
First 
author, 
Year of 
publication 
Study  
population, 
Age, 
BMI 
Duration 
intervention 
period,  
Study design 
 
Total 
fat 
(en%)  
 
C16:0 
C18:0 
(en%) 
Difference 
between diets  
C16:0  
C18:0 (en%)  
 
Main source  
C16:0  
C18:0  
 
 
Lipids and 
lipoproteins 
 
 
Hematological 
markers 
 
 
Other  
markers 
Grande, 
1970 [15] 
32 men 
40-65 y 
NR 
18 days 
Latin-square  
34 15  
10 
6 
8 
Palm oil 
 
Cocoa 
butter  
TAG = 
TC ↓ 
 
  
Bonanome,  
1988 [16] 
11 men 
64±4.0 y 
24±1.7 kg/m2 
21 days 
Cross-over (no 
WO) 
40 18 
17 
 
15 Palm oil 
 
Hydro-
genated 
soybean oil 
 
TAG = 
TC ↓ 
VLDL-C = 
LDL-C ↓ 
HDL-C = 
  
Tholstrup, 
1994 [17] + 
1995 [25] 
15 men 
24.9 (22-30) y 
23.2 (20.4-
26.4) kg/m2 
21 days 
Cross-over 
40 16$ 
14 
14 Palm oil  
 
Shea butter 
TAG = 
TC ↓ 
VLDL-C =  
LDL-C ↓ 
HDL-C ↓ 
ApoB ↓ 
ApoA1 ↓ 
Lp[a] ↑ 
FVIIc ↓ 
PAI-1 activity =  
PAI-1 antigen =  
tPA activity = 
tPA antigen =   
EFA =  
 
 
Dougherty, 
1995 [18] 
 
10 men 
37.4±6.6 y 
25.2±2.5 kg/m2 
40 days 
Cross-over (no 
WO) 
27-29 7 5 
6 
Palm oil 
 
Shea butter 
TAG = 
TC ↓ 
LDL-C ↓ 
HDL-C = 
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Schwab, 
1996 [19] + 
1997 [26] 
12 women$$ 
(premenopaus
al) 
23.5±3.1 y 
22.1±2.4 kg/m2 
28 days 
Cross-over 
37 12 
7 
3 
5 
Palm oil, 
butter 
 
Cocoa 
butter 
TAG = 
NEFA =$$ 
TC ↓ 
VLDL-C = 
LDL-C = 
HDL-C ↓ 
ApoB = 
ApoA1 ↓ 
 CETP 
activity ↓ 
Glucose =$$ 
Insulin =$$ 
Nestel, 
1998 [21] 
15 subjects 
(mildly 
hyperchol men 
and women#) 
51±7 y 
26.2±3.9 kg/m2 
35 days 
Cross-over  
(no WO) 
41-42 8## 
 
 
±5 
 
Palm olein 
 
Fully 
hydrogenate
d soybean 
oil 
TAG = 
TC =  
LDL-C = 
HDL-C =  
  
Snook, 
1999 [23] 
16 women 
(premenopaus
al) 
28±6 y 
NR 
35 days 
3x3  
cross-over 
40 13 10 
11 
Tripalmitin  
 
Tristearin  
TAG = 
TC ↓ 
LDL-C ↓ 
HDL-C = 
ApoB = 
ApoA1 = 
 CETP 
activity =  
LCAT 
activity =  
 
Kelly, 
2001 [22] 
13 men 
35±12 y 
26±3.3 kg/m2 
28 days 
Cross-over 
27-28 8 
7 
6 
5 
Palm stearin 
and/or palm 
olein  
 
Hydrogenat
ed canola  
TAG = 
TC = 
LDL-C = 
HDL-C = 
FVIIc = 
MPV ↓ 
Fibrinogen = 
Plasminogen = 
WBC = 
RBC =  
Hgb = 
PLT =  
APTT = 
ATIII = 
48 
 
 
Kelly, 
2002 [24] 
9 men 
39±10 y 
25±2.5 kg/m2 
21 days 
Cross-over 
28-29 7 
4 
1 
2 
 
Potato 
crisps, 
shortbread 
biscuits, 
muesli bars 
 
Milk 
chocolate 
TAG = 
TC = 
LDL-C =  
HDL-C = 
MPV = 
WBC =  
RBC =  
Hgb = 
PLT = 
 
Ng, 
2018 [12] 
64 women 
21 men 
20-60y 
21-30 kg/m2 
 
56 days 
Parallel 
35 7 
8 
5 
7 
IE Palm 
olein 
 
IE 
hydrogenate
d soybean 
oil 
 
TAG ↓ 
TC = 
LDL-C =  
HDL-C = 
ApoB = 
ApoA1 = 
Lp[a] = 
 Glucose = 
Insulin = 
C-peptide =  
 
Meng, 
2019 [20] 
20 
postmenopaus
al women 
(mildly 
hyperchol^) 
64±7 y 
26.4±3.4 kg/m2 
35 days 
Cross-over  
30 14* 
10 
8 
9 
Palm oil  
 
Cocoa 
butter 
 
 
TAG = 
TC ↓ 
VLDL-C = 
LDL-C ↓ 
HDL-C ↓ 
ApoB = 
ApoA1 = 
Lp[a] = 
PT = 
PTT = 
Glucose = 
Insulin =  
CRP = 
TNF-a = 
IL-6 = 
SAA-1 = 
sICAM-1 = 
sICAM-3 = 
sVCAM-1 = 
E-selectin = 
P-selectin = 
Thrombo-
modulin =  49 
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Supplemental Table 4. Postprandial effects of substituting fats low in palmitic acid (C16:0) sn-2 contents with fats high in C16:0 sn-2 contents on 
cardiometabolic risk markers. 
First 
author, 
Year of 
publication 
Population,  
Age, 
BMI, 
Follow-up 
 
Total 
energy 
(kcal) 
 
Total fat 
in grams  
(en%)  
C16:0  
content 
in grams 
(en%) 
Source  
Low sn-2 
High sn-2 
C16:0  
sn-2 in fat 
blends 
(%a) 
Solid 
fat at 
37°C 
(%) 
 
Lipids and 
lipopro-
teins 
 
Hemato-
logical 
markers 
 
 
Other  
markers 
Zampelas, 
1994 [35] 
16 men 
24.8±2.6 y 
22.7±2.4 kg/m2 
6h 
662 40  
(54en%) 
 
12  
(16en%) 
 
 
Palm olein 
 
IE blend of 
palm 
stearine with 
sunflower oil 
5.9 
 
72.7 
wt% 
NR TAG =  
NEFA = 
 Glucose = 
Insulin = 
GIP =  
Summers, 
1998 [36] 
2 men 
6 women 
30.5 (18-55) y 
24 (19-30) kg/m2 
6h 
932 60 
(58en%) 
18 
(17en%) 
NR 5.9 
 
67.8  
mol% 
NR TAG =  
NEFA =  
 Glucose = 
Insulin = 
Yli-Jokipii, 
2001 [32] 
10 women 
(premenopausal) 
26.9±2.56 y 
18.5-25 kg/m2 
6h 
NR 55g/m2 
body 
surface 
area 
17g/m2 
body 
surface 
area 
Palm oil 
 
IE palm oil 
 
9 
 
31 
mol% 
0 
 
0 
TAG ↓ 
NEFA =  
VLDL-C = 
CM-C =  
 Glucose =  
Insulin = 
 
Yli-Jokipii, 
2003 [27] 
2 men 
7 women 
(premenopausal) 
24±3 y 
21.5±2.5 kg/m2 
8h 
NR 55g/m2 
body 
surface 
area 
17g/m2 
body 
surface 
area 
IE Lard 
 
Lard 
52 
 
69 
mol% 
11.0$ 
 
12.5 
TAG =# 
NEFA = 
TC = 
 
 Glucose =  
Insulin =  
51 
 
 
Berry, 
2007 [33] 
 
20 men 
28.8±10.3 y 
23.2±2.6 kg/m2 
6h 
853 50 
(53en%) 
14 
(15en%) 
Palm oil 
 
IE palm oil 
7.2 
 
37.2 
mol% 
3.6 
 
15.2 
TAG = 
TC = 
LDL-C =  
HDL-C = 
FVIIa = 
WBC = 
Glucose = 
Insulin =  
 
Sanders, 
2011 [7] 
Filippou, 
2014 [37] 
25 men 
25 women 
(premenopausal) 
±24.8 y 
±23.5 kg/m2 
8h 
846 50 
(53en%) 
20 
(22en%) 
Palm olein 
 
IE palm olein 
9.2 
 
39.1 
mol% 
0 
 
4.7 
 
TAG = 
NEFA = 
TC = 
ApoB48 = 
 
 Glucose = 
Insulin = 
C-peptide =  
GIP ↓ 
PYY= 
IL-6 = 
IL-8 = 
TNF-α = 
E-selectin = 
Hall, 
2014 [34] 
11 men 
50±7 y 
27.6±3.1 kg/m2 
6h 
1047 75 
(64en%) 
30 
(26en%) 
Palm olein 
 
IE palm olein 
9.8 
 
45.9 
mol% 
NR 
 
TAG =^ 
NEFA = 
TC = 
 
  
Hall, 
2017 [28] 
12 men 
20.5±1.1 y 
22.4±2.8 kg/m2  
4h 
832 52 
56en% 
26 
28en% 
PSt/PK 
 
IE PSt/PK 
36.0 
 
54.7 
mol% 
24^^ 
 
21 
TAG ↑ 
 
 Glucose = 
Insulin =  
GIP = 
PYY = 
Markers are significantly lower (↓), higher (↑) or not significantly different (=) after intake of fats high in C16:0 sn-2 contents compared with fats low in C16:0 sn-2 contents. 
a=% of total fatty acids at sn-2. $= 12.5% Lard and 11.0% IE lard was solid at 35°C, and 8.3% and 6.5% at 40°C respectively. No values reported for 37°C [27]. #=iAUC of VLDL-
TAG was smaller after lard [27]. ^=TAG iAUC of 0 to 4 hours after IE palm olein was lower than after palm olein (p=0.024). Chylomicron TAG was lower at 4h after IE palm olein 
compared to palm olein (p=0.038) [34]. ̂ ^= 24% PSt/PK and 21% IE PSt/PK was solid at 35°C, and 17 and 11% at 40°C respectively. No values for 37°C [28]. Abbreviations: apoB48, 
apolipoprotein B48; CM-C, chylomicron cholesterol; en%, % of total energy; FVIIa, activated factor VII; GIP, glucose-dependent insulinotropic polypeptide; HDL-C, high-density 
lipoprotein cholesterol; IE, interesterified; IL, interleukin; LDL-C, low-density lipoprotein cholesterol; NEFA, non-esterified fatty acids; NR, not reported; PSt/PK, palm stearin 
blended with palm kernel; PYY, peptide YY; TAG, triacylglycerol; TC, total cholesterol; TNF, tumor necrosis factor; VLDL, very low-density lipoprotein; WBC, white blood cells; 
wt, weight; y, year. 52 
 
 
Supplemental Table 5. Postprandial effects of substituting fats low in stearic acid (C18:0) sn-2 contents with fats high in C18:0 sn-2 contents on 
cardiometabolic risk markers. 
First 
author, 
Year of 
publication 
Population,  
Age, 
BMI, 
Follow-up 
 
Total 
energy 
(kcal) 
Total 
fat in 
grams  
(en%)  
C18:0  
content 
in grams 
(en%) 
 
Source  
Low sn-2 
High sn-2 
C18:0  
sn-2 in fat 
blends 
(%a) 
Solid 
at 
37°C 
(%) 
 
 
Lipids and  
lipoproteins 
 
Hemato-
logical 
markers 
 
 
Other  
markers 
Summers, 
1999 [29] 
14 women 
49 (29-70) y 
27.5 (20.6-52.8) 
kg/m2  
6h 
932 60 
(58en
%) 
18 
(18en%) 
NR NR 
 
83.3 
NR TAG =  
NEFA = 
 Glucose = 
Insulin = 
Sanders, 
2003 [30] 
17 men 
38.2±11.1 y 
24.5±2.9 kg/m2 
6h 
749 50 
(60en
%) 
17 
(20en%) 
Cocoa butter 
 
IE cocoa 
butter 
NR 
 
NR# 
 
 
TAG ↓ 
TC = 
LDL-C = 
 
FVIIa ↓  
Berry,  
2007 [14] 
16 men 
26.8±8.0 y 
23.7±3.7 kg/m2  
8h 
853 50 
(53en
%) 
26 
(28en%) 
Native or IE 
shea butter 
blended with 
HOSO 
3.1 
 
22.8 
mol% 
22.2 
 
41.2 
TAG = 
NEFA = 
TC = 
LDL-C = 
HDL-C =     
FVIIa = 
WBC = 
Glucose = 
Insulin = 
Robinson, 
2009 [31] 
10 non-obese men 
(55.8±7.0y, 
26.6±2.5 kg/m2) 
11 obese men 
(59.3±6.0y, 
32.9±4.3 kg/m2), 6h 
NR 86-
102 
(76en
%) 
(1g/kg 
body 
mass) 
25-30 
(21en%) 
Canola stearin 
(EIE, CIE, 
native) 
blended with 
HOSO 
0.5 
 
0.6 
 
25.5 
wt% 
5.4 
 
5.6 
 
18.6 
Non-obese:  
TAG = 
Obese: 
TAG ↓$ 
Both: 
NEFA =  
TC = 
LDL-C = 
 Both: 
Glucose =  
Insulin = 
53 
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Supplemental Table 6. Postprandial effects of substituting fats high in palmitic acid (C16:0) with fats high in stearic acid (C18:0) on cardiometabolic risk 
markers. 
 
 
First author, 
year of 
publication 
Population,  
Age, 
BMI, 
Postprandial  
follow-up 
 
 
Total 
energy 
(kcal) 
 
 
Total fat 
in grams 
(en%) 
 
Content  
C16:0 
C18:0  
(g) 
 
Content  
C16:0  
C18:0  
(en%) 
 
 
Source  
C16:0 
C18:0 
 
 
Lipids and 
lipopro-
teins 
 
 
Hemato-
logical 
markers 
 
 
 
Other  
markers  
Mennen, 
1998 [42] 
91 women 
(postmenopausal) 
75.7±5.2 y 
27.7±4.1 kg/m2  
6-7 hours 
948- 
889 
 
55.7-
49.3 
(53-
50en%) 
22 
 
19 
 
21 
 
19 
NR TAG = 
 
FVIIa = 
  
 
 
  
Jensen, 
1999 [38] 
15 women 
(premenopausal) 
8 normal-weight  
(27±2 y, 19.2-23.7 
kg/m2) 
7 overweight  
(29±3 y, 28.8-47.5 
kg/m2) 
8 hours 
406kcal/m2 
body 
surface 
area 
29g/m2 
(65en%) 
12g/m2 
 
5g/m2 
27 
 
10 
Palm oil 
 
Lard 
Both:  
TAG = 
 
 Both:  
Insulin = 
Leptin = 
 
Sanders, 
2000 [39] 
11 men 
5 women 
(premenopausal) 
25.5 (18-32) y 
23.2 (20.1-27.8) 
kg/m2 
7 hours 
1242 90 
(65en%) 
37 
 
36 
27 
 
26 
Palm oil 
 
Hydro-
genated  
and IE 
HOSO 
TAG = 
 
FVIIa = 
FVIIc = 
 
  
55 
 
 
Tholstrup, 
2001 [41] + 
2003 [44] + 
2004 [43] 
16 men 
23.4±2.4 y 
23±2 kg/m2  
8 hours 
1672#  75# 
(50.6 
en%##) 
32# 
 
34#  
17 
 
18 
IE blend of 
tripalmitin 
or 
tristearin 
with 
HOSO 
TAG = 
NEFA = 
VLDL-C = 
LDL-C =  
HDL-C = 
ApoB =  
ApoA1 =  
Lp[a] = 
FVIIa = 
FVIIc = 
PAI-1 
antigen =  
tPA 
activity = 
CETP 
activity =  
LPL  
activity = 
 
Teng, 
2011 [40] 
10 men 
21.9±0.7 y 
21.0±1.6 kg/m2  
4 hours 
754 50 
(60en%) 
17 
 
9 
21 
 
10 
Palm olein 
 
Lard 
TAG ↓ 
NEFA = 
 Glucose =  
Insulin =  
Leptin =  
IL-6 = 
TNF-α = 
IL-1ß = 
Sanders, 
2011 [7] 
Filippou, 
2014 [37] 
25 men 
25 women 
(premenopausal) 
±24.8y, 
±23.5kg/m2 
8 hours 
846 50 
(53en%) 
20 
 
9 
22 
 
9 
Palm olein 
 
Lard 
TAG ↓ 
NEFA ↓ 
TC = 
ApoB48 = 
 
 Glucose =  
Insulin = 
C-peptide 
=  
GIP ↓ 
PYY= 
IL-6 = 
IL-8 = 
TNF-α = 
E-selectin 
= 
Markers are significantly lower (↓), higher (↑) or not significantly different (=) after intake of fats high in C18:0 compared with fats high in C16:0. #=per 75kg body weight. 
Range of fat intake was 65-85 grams [41]. ##=50.6 en% was reported. However, our calculations indicate 40.4 en% [41]. Abbreviations: apoB, apolipoprotein B; apoA1, 
apolipoprotein A1; CETP, cholesteryl ester transfer protein; en%, % of total energy; FVIIa, activated factor VII; FVIIc, Factor VII coagulant activity; GIP, glucose-dependent 
insulinotropic polypeptide; HDL-C, high-density lipoprotein cholesterol; HOSO, high oleic sunflower oil; IE, interesterified; IL, interleukin; Lp[a], lipoprotein [a]; LPL, lipoprotein 
lipase; LDL-C, low-density lipoprotein cholesterol; NEFA, non-esterified fatty acids; NR, not reported; PAI, plasminogen activator inhibitor; PYY, peptide YY; TAG, triacylglycerol; 
TC, total cholesterol; TNF, tumour necrosis factor; tPA, tissue plasminogen activator; VLDL-C, very-low density lipoprotein cholesterol; wt, weight; y, year. 
56 
 
 57 
 
 58 
 
  
59 
CHAPTER 3
Dietary palmitic acid and stearic acid do not differently affect 
ABCA1-mediated cholesterol efflux capacity in healthy men and 
postmenopausal women: a randomized controlled trial 
M.A. van Rooijen, J. Plat, W.A.M. Blom, P.L. Zock, R.P. Mensink
Submitted
EM
BA
RG
OE
D
This chapter is embargoed at request
81 
CHAPTER 4
Effects of two consecutive mixed meals high in palmitic acid or 
stearic acid on 8-hour postprandial lipemia and glycemia in 
healthy men and postmenopausal women 
M.A. van Rooijen, J. Plat, W.A.M. Blom, P.L. Zock, R.P. Mensink
To be submitted 
EM
BA
RG
OE
D
This chapter is embargoed at request
103 
CHAPTER 5 
Effects of dietary palmitic acid and stearic acid on lipoprotein 
subfractions, ABCA1-mediated cholesterol efflux and apoA-I 
secretion in healthy men and postmenopausal women 
M.A. van Rooijen, J. Plat, D.M. Jacobs, W.A.M. Blom, R.P. Mensink
To be submitted 
EM
BA
RG
OE
D
This chapter is embargoed at request
123 
CHAPTER 6 
A comparison of the postprandial effects from high-fat, high-
protein or high-carbohydrate meals on ABCA1-mediated 
cholesterol efflux and apoA-I secretion in overweight or slightly 
obese men 
M.A. van Rooijen, J. Plat, P.J. Joris, E.T.H.C. Smeets, R.P. Mensink
To be submitted 
EM
BA
RG
OE
D
This chapter is embargoed at request
139 
CHAPTER 7 
General discussion
EM
BA
RG
OE
D
This chapter is embargoed at request
157 
APPENDIX I 
Summary 
Samenvatting 
Valorization 
APPENDIX I  Summary 
 158 
Summary 
Coronary heart disease (CHD), also known as coronary artery disease (CAD) or ischemic heart 
disease (IHD), is a common type of cardiovascular disease (CVD) and a major cause of death 
worldwide. CHD is caused by a disrupted blood flow to the heart due to the development of 
an atherosclerotic plaque in the coronary arteries. LDL-cholesterol is a well-established risk 
factor for CHD, as high concentrations are positively and causally related to CHD. In contrast 
to LDL-cholesterol, high concentrations of HDL-cholesterol have been associated with a 
reduced risk for CHD. However, recent drug interventions that increased HDL-cholesterol 
failed to reduce this risk. Thus, HDL-cholesterol is not causally related to CHD and it is now 
believed that we should focus on HDL functionality instead of the concentration of HDL-
cholesterol. One of the functionalities of HDL is its capacity to perform cholesterol efflux 
from lipid-loaded macrophages, known as cholesterol efflux capacity (CEC). Indeed, 
cholesterol efflux mediated via ATP-binding cassette transporter A1 (ABCA1-mediated CEC) 
has been inversely associated with CHD-risk. For ABCA1-mediated CEC, interaction between 
ABCA1 (present on many cells including macrophages) and apolipoprotein A-I (apoA-I; 
component of HDL) is crucial. Besides, also other fasted and postprandial markers are known 
to be relevant for the risk of developing CHD, such as those related to lipemia, glucose-insulin 
homeostasis, low-grade inflammation and/or endothelial function.  
 
Diet and other lifestyle factors such as exercise or smoking affect the risk of developing 
atherosclerosis and subsequent CHD. One of the dietary factors that has been linked to CHD-
risk is saturated fat, because the intake of saturated fat is positively associated with fasted 
serum LDL-cholesterol concentrations. However, saturated fat is an umbrella term for 
different saturated fatty acids that may exert different effects on LDL-cholesterol and other 
CHD-risk markers. Indeed, it is well-known that the two most abundant saturated fatty acids 
in many Western diets, palmitic acid (C16:0) and stearic acid (C18:0), differently affect 
cholesterol concentrations, i.e. stearic acid lowers LDL- and HDL-cholesterol compared with 
palmitic acid. However, it is less clear whether these fatty acids also differently affect other 
risk markers such as cholesterol efflux. Therefore, the research in this dissertation is mainly 
focused on the effects of dietary fat – predominantly the saturated fatty acids palmitic acid 
and stearic acid – on conventional and emerging cardiometabolic risk markers among which 
ABCA1-mediated CEC. For this, the results of a systematic review and two human dietary 
intervention studies have been described in this dissertation.   
 
In chapter 2, existing literature describing the effects of stearic acid- versus palmitic acid-rich 
fats on cardiometabolic risk markers has been reviewed. In addition, it was also examined 
whether interesterification (shuffling fatty acids between and within triacylglycerols) of 
palmitic acid- or stearic acid-rich fats affects these risk markers, because interesterification 
is nowadays widely used by the food industry to increase the suitability of fats for certain 
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foods. Indeed, it was found that substituting palmitic acid with stearic acid lowers fasted 
serum LDL- and HDL-cholesterol. Interesterification of palmitic acid- or stearic acid-rich fats 
does not differently affect fasted lipids and (apo)lipoproteins when compared to their 
corresponding non-interesterified (native) fats. However, during the postprandial phase, 
lipemia is attenuated if the solid fat content of the fat blend at 37°C is increased by 
interesterification due to changes in palmitic acid or stearic acid sn-2 contents, while no 
evidence was found that solely substituting palmitic acid with stearic acid affects 
postprandial lipemia. How palmitic acid- or stearic acid-rich fats as well as interesterification 
of these fats affects other cardiometabolic risk markers needs further investigation before 
conclusions could be drawn.  
 
In chapters 3, 4 and 5, the results of a human dietary intervention study with twenty men 
and fourteen postmenopausal women are described to examine longer-term and 
postprandial effects of palmitic-acid versus stearic-acid intakes on cholesterol efflux and 
other cardiometabolic risk markers.  
 The longer-term effects of 4-week diets rich in palmitic acids or stearic acids on 
cardiometabolic risk markers are reported in chapter 3. As expected, stearic-acid intake 
lowered fasted LDL- and HDL-cholesterol compared with palmitic-acid intake. ABCA1-
mediated CEC was however comparable between the two diets, even though apoA-I 
concentrations were also lower on the stearic-acid diet. The lower HDL-cholesterol 
concentrations may at least partly be explained by an increased mass of cholesteryl ester 
transfer protein (CETP). In addition, the results suggest that insulin sensitivity in women as 
well as low-grade inflammation in both men and women might be unfavorably affected by 
stearic-acid intake.  
 In chapter 4, results of the postprandial tests performed at the end of both dietary 
intervention periods are described. Participants received two consecutive mixed meals high 
in palmitic acid- or stearic acid-rich fat blends during each postprandial test and effects on 
postprandial lipemia and glycemia were studied. Consumption of the meals containing the 
stearic acid-rich fat lowered postprandial lipemia as compared with the palmitic-acid meals. 
In addition, our results indicate that the number of chylomicrons after intake of the stearic-
acid meals was lower. It is hypothesized that these observed differences are due to the 
higher solid fat content of the stearic acid-rich fat at 37°C. As triacylglycerol-rich lipoproteins 
are positively related to CHD, the effects of stearic acid on postprandial lipemia appear to be 
more favorable than those of palmitic acid. No pronounced differences in parameters 
related to postprandial glycemia were found between the fatty acids, although the changes 
over time in C-peptide – a marker of insulin secretion – differed. C-peptide concentrations 
were higher after the first stearic acid-rich meal and peaked earlier after the second stearic-
acid rich meal when compared with the palmitic acid-rich meals. In addition, concentrations 
of non-esterified fatty acids (NEFA) were markedly lower after intake of the stearic acid-rich 
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fats. It is hypothesized that lower postprandial NEFA concentrations are more favorable, but 
a direct link between NEFA and CHD-risk has not been established so far.  
 Results of the 4-week diets on fasted lipoprotein subfractions, and fasted and 
postprandial apoA-I concentrations, apoA-I secretion and ABCA1-mediated CEC can be found 
in chapter 5. These results indicate that palmitic-acid and stearic-acid diets differently affect 
cholesterol and triacylglycerol concentrations in several VLDL, LDL, and HDL subfractions. 
Cholesterol concentrations on the stearic-acid diet were higher in subfractions of VLDL and 
lower in those of LDL and HDL compared with the palmitic-acid diet. On the other hand, 
triacylglycerol concentrations were higher in VLDL, LDL, and HDL subfractions on the stearic-
acid diet. As triacylglycerol concentrations within lipoprotein subfractions have been 
positively associated with cardiovascular disease, this appears to be an unfavorable effect of 
stearic acid. No significant differences between the diets were found in fasted and 
postprandial ABCA1-mediated CEC as well as apoA-I secretion, although fasted apoA-I 
concentrations were lower on the stearic-acid diet.  
 
Lastly, we have compared in eighteen men the effects of acute consumption of high-fat, 
high-protein, or high-carbohydrate meals on postprandial ABCA1-mediated CEC and 
(secretion of) apoA-I. These results are reported in chapter 6. We did not observe any 
differences between the meals in postprandial ABCA1-mediated CEC and apoA-I 
concentrations, even though the high-protein and high-fat meals increased apoA-I secretion.  
 
In summary, the research in this dissertation was performed to get more insight into the 
effects of dietary fat, particularly the two most commonly consumed saturated fatty acids 
palmitic acid and stearic acid, on conventional and emerging cardiometabolic risk markers, 
with an emphasis on ABCA1-mediated CEC. Our findings have shown that palmitic acid and 
stearic acid have comparable effects on ABCA1-mediated CEC, but differently affect several 
other fasting and postprandial cardiometabolic risk markers. Thus, at this moment it cannot 
be excluded that palmitic acid and stearic acid differently affect cardiometabolic health via 
mechanisms other than LDL-cholesterol. In addition, no evidence was found that acute 
intakes of high-fat, high-protein or high-carbohydrate meals differently affect postprandial 
ABCA1-mediated CEC.
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Nederlandse samenvatting 
Coronaire hartziekten (CHZ), ook wel bekend als ischemische hartziekten, zijn de meest 
voorkomende hart- en vaatziekten en een veelvoorkomende oorzaak voor sterfte 
wereldwijd. CHZ worden veroorzaakt door een verminderde bloedtoevoer naar het hart 
vanwege aderverkalking (atherosclerose) in de coronaire slagaderen. Een welbekende risico 
factor voor CHZ is LDL-cholesterol, omdat hoge concentraties positief en causaal gerelateerd 
zijn aan CHZ. Naast LDL-cholesterol zijn er ook andere markers gerelateerd aan het risico op 
CHZ. Hoge concentraties HDL-cholesterol zijn bijvoorbeeld geassocieerd met een verlaagd 
risico op CHZ. Desalniettemin is het met recente farmacologische interventies die HDL-
cholesterol verhogen niet gelukt om het CHZ-risico te verlagen. Daaruit is gebleken dat HDL-
cholesterol niet causaal gerelateerd is aan CHZ en wetenschappers denken nu dat de 
functionaliteit van de HDL-deeltjes belangrijker is dan de hoeveelheid HDL-cholesterol. Een 
van de functies van HDL is het accepteren van cholesterol uit lipide-rijke macrofagen, dit 
noemen we cholesterol efflux capaciteit (CEC). Cholesterol efflux via ATP-bindende cassette 
transporter A1 (ABCA1-gemedieerde CEC) is negatief geassocieerd met het risico op CHZ. 
Voor ABCA1-gemedieerde CEC is interactie tussen ABCA1 (aanwezig op verschillende cellen 
waaronder macrofagen) en apolipoproteïne A-I (apoA-I; onderdeel van HDL) cruciaal. 
Daarnaast zijn ook andere nuchtere en postprandiale biomarkers relevant voor het risico op 
CHZ, zoals markers gerelateerd aan lipemie, glucose-insuline homeostase, lichte ontsteking 
en/of endotheel functie.  
 
Dieet en overige leefstijlfactoren zoals sporten en roken hebben invloed op het risico om 
aderverkalking te ontwikkelen, wat weer kan leiden tot CHZ. Een van de factoren uit het dieet 
gelinkt aan het risico op CHZ is verzadigd vet, omdat de inname van verzadigd vet positief 
geassocieerd is met nuchtere serum LDL-cholesterol waarden. Verzadigd vet is echter een 
verzamelnaam voor verschillende verzadigde vetzuren die mogelijk verschillende effecten 
hebben op LDL-cholesterol en andere risicomarkers voor CHZ. Het is inderdaad bekend dat 
de twee meest voorkomende verzadigde vetzuren in menig Westers dieet, palmitinezuur 
(C16:0) en stearinezuur (C18:0), verschillende effecten hebben op het cholesterolgehalte. 
Stearinezuur verlaagd namelijk LDL- en HDL-cholesterol ten opzichte van palmitinezuur. We 
weten echter nog niet zo goed of deze vetzuren ook verschillende effecten hebben op 
andere risicomarkers zoals cholesterol efflux. Daarom ligt de focus van het onderzoek 
beschreven in dit proefschrift op de effecten van voedingsvet – voornamelijk de verzadigde 
vetzuren palmitinezuur en stearinezuur – op cardiometabole risicomarkers waaronder 
ABCA1-gemedieerde CEC. Hiervoor hebben we de resultaten van een systematische review 
en twee humane interventies studies beschreven. 
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In hoofdstuk 2 is de bestaande literatuur over de effecten van vetten rijk aan stearinezuur 
versus vetten rijk aan palmitinezuur op cardiometabole risicomarkers besproken. Daarnaast 
is er ook gekeken of interesterificatie (uitwisselen van vetzuren tussen en binnen 
triglyceriden) van palmitine- of stearine-rijke vetten een effect heeft op deze risicomarkers, 
omdat interesterificatie momenteel veel wordt gebruikt door de voedingsindustrie om de 
toepasbaarheid van vetten te verhogen voor bepaalde voedingsmiddelen. Zoals verwacht 
verlaagd vervanging van palmitinezuur door stearinezuur de nuchtere serum concentraties 
van LDL- en HDL-cholesterol. Interesterificatie van vetten rijk in palmitinezuur of 
stearinezuur had geen effect op nuchtere lipiden en (apo)lipoproteïnen. Daarentegen was 
postprandiale lipemie verminderd als door interesterificatie de veranderingen in de 
hoeveelheid palmitine- of stearinezuur op sn-2 het gehalte aan vast vet bij 37°C verhoogden. 
Er was echter geen bewijs dat enkel het vervangen van palmitinezuur door stearinezuur een 
effect heeft op postprandiale lipemie. Er is meer onderzoek nodig om conclusies te trekken 
over de effecten van (interesterificatie van) vetten rijk aan stearinezuur of palmitinezuur op 
andere cardiometabole risicomarkers.  
 
In hoofdstuk 3, 4 en 5 zijn de resultaten beschreven van een humane voedingsinterventie 
studie met twintig mannen en veertien postmenopauzale vrouwen waarin zowel de langere-
termijn als postprandiale effecten van de inname van palmitinezuur versus stearinezuur op 
cholesterol efflux en andere cardiometabole risicomarkers zijn bestudeerd.  
 De langere termijneffecten van een 4-weken dieet rijk in palmitinezuur of 
stearinezuur op cardiometabole risicomarkers zijn gerapporteerd in hoofdstuk 3. Zoals 
verwacht verlaagde de inname van stearinezuur nuchtere LDL- en HDL-cholesterol waarden 
vergeleken met de inname van palmitinezuur. Echter was er ondanks de verlaging van HDL-
cholesterol en apoA-I-concentraties op het stearine-dieet geen verschil in ABCA1-
gemedieerde CEC tussen de diëten. De lagere HDL-cholesterol concentraties kunnen 
mogelijk verklaard worden door de hogere hoeveelheid cholesterylestertransferproteïne 
(CETP). Daarentegen waren zowel insulinegevoeligheid in vrouwen als inflammatiewaarden 
in de gehele populatie mogelijk negatief beïnvloed door het stearine-dieet.  
 In hoofdstuk 4 zijn de resultaten van de postprandiaal testen aan het eind van beide 
voedingsinterventies beschreven. Deelnemers kregen twee opeenvolgende maaltijden rijk 
aan palmitinezuur of stearinezuur tijdens elke postprandiaal test en de effecten op 
postprandiale lipemie en glycemie zijn bestudeerd. Inname van de maaltijden rijk aan 
stearinezuur verlaagde postprandiale lipemie vergeleken met de maaltijden rijk aan 
palmitinezuur. Daarbij laten de resultaten ook zien dat er minder chylomicronen waren na 
inname van de stearine-rijke maaltijden. De hypothese is dat deze verschillen veroorzaakt 
worden door het hogere gehalte aan vast vet in het stearine-rijke vet bij 
lichaamstemperatuur. Aangezien triglyceride-rijke lipoproteïnen positief gerelateerd zijn aan 
CHZ, lijken de effecten van stearinezuur op postprandiale lipemie gunstiger te zijn dan die 
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van palmitinezuur. Er waren geen uitgesproken verschillen waarneembaar in markers 
gerelateerd aan postprandiale glycemie, al waren de veranderingen over tijd in C-peptide – 
een marker voor insuline secretie – verschillend tussen de vetzuren. De concentratie C-
peptide was hoger na de eerste stearine-rijke maaltijd en piekte eerder na de tweede 
stearine-rijke maaltijd ten opzichte van de palmitine-rijke maaltijden. Daarbij was de 
concentratie vrije vetzuren sterker verlaagd na inname van de stearine-rijke maaltijden. De 
hypothese is dat lagere postprandiale vrije vetzuren gunstiger zijn, maar een directe link 
tussen vrije vetzuren en het risico op CHZ is tot op heden niet vastgesteld.   
 
 Resultaten van de 4-weken diëten op nuchtere lipoproteïnen subfracties alsmede 
op nuchtere en postprandiale apoA-I waarden, apoA-I secretie en ABCA1-gemedieerde CEC 
zijn gerapporteerd in hoofdstuk 5. Deze resultaten laten zien dat diëten rijk aan palmitine of 
stearinezuur verschillende effecten hebben op nuchtere cholesterol en triglyceride 
concentraties in meerdere VLDL, LDL en HDL subfracties. Cholesterolwaarden tijdens het 
stearine-dieet waren hoger in subfracties van VLDL en lager in subfracties van LDL en HDL 
vergeleken met het palmitine-dieet. Daarentegen waren de triglyceride concentraties in 
VLDL, LDL en HDL subfracties hoger op het stearine-dieet. Aangezien triglyceride 
concentraties binnen lipoproteïne subfracties positief geassocieerd zijn met hart- en 
vaatziekten, lijkt dit een ongunstig effect van stearinezuur. Er zijn geen significante 
verschillen gevonden tussen diëten in nuchtere en postprandiale ABCA1-gemedieerde CEC 
alsmede apoA-I secretie, ondanks dat nuchtere apoA-I concentraties lager waren op het 
stearine-dieet.  
 
Tot slot hebben we in achttien mannen de effecten vergeleken van de acute consumptie van 
hoog-vet, hoog-eiwit of hoog-koolhydraat maaltijden op postprandiale ABCA1-gemedieerde 
CEC en (secretie van) apoA-I. Deze resultaten zijn beschreven in hoofdstuk 6. Er zijn geen 
verschillen gevonden tussen de maaltijden wat betreft serum ABCA1-gemedieerde CEC en 
apoA-I concentraties, terwijl de hoog-vet en hoog-eiwit maaltijden apoA-I secretie 
verhoogden.  
 
Het onderzoek in dit proefschrift was uitgevoerd om meer inzichten te krijgen in de effecten 
van voedingsvetten, voornamelijk de twee meest geconsumeerde verzadigde vetzuren 
palmitinezuur en stearinezuur, op een breed scala aan cardiometabole risicomarkers, met 
de nadruk op ABCA1-gemedieerde CEC. Onze bevindingen hebben laten zien dat 
palmitinezuur en stearinezuur vergelijkbare effecten hebben op ABCA1-gemedieerde CEC, 
maar verschillende effecten hebben op een verscheidenheid aan andere nuchtere en 
postprandiale cardiometabole risicomarkers. Op dit moment kan het dus niet uitgesloten 
worden dat palmitinezuur en stearinezuur verschillende effecten hebben op de 
cardiometabole gezondheid via mechanismes niet gerelateerd aan LDL-cholesterol.  
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Daarnaast laat het onderzoek in dit proefschrift zien dat er geen verschillen zijn tussen 
innames van hoog-vet, hoog-eiwit of hoog-koolhydraat maaltijden in postprandiale ABCA1-
gemedieerde CEC.  
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Valorization 
Societal and economic relevance 
Over the past decades, cardiovascular diseases (CVDs) have been the leading cause of death 
worldwide [1]. Currently, the number of CVD-related deaths is still growing. In 2016, 
approximately one third of all global deaths was due to CVDs. In addition, living with CVD or 
having a high CVD-risk lowers the health-related quality of life including physical and mental 
health [2]. The high number of CVDs also results in a high economic burden. In 2010, the 
global costs of CVDs added up to approximately 863 billion US dollars and it has been 
estimated that these costs will increase to 1044 billion US dollars in 2030 [3]. In Europe alone, 
the costs of CVDs are estimated to be 210 billion euros per year [4].  
 
Coronary heart disease (CHD) is a common type of CVD and is often caused by 
atherosclerosis. Diet is one of the underlying causes for developing CHD and therefore 
dietary recommendations are needed to prevent CHD [1]. In order to develop these 
recommendations, dietary intervention studies are required that unravel the complex 
relationship between nutrition and CHD-risk. It is well-known that dietary saturated fat 
increases LDL-cholesterol, a risk factor for CHD, compared with unsaturated fats. It is 
therefore advised to keep the intake of saturated fat below 10% of daily energy [5]. However, 
saturated fat is an umbrella term for different saturated fatty acids that may exert different 
effects on CHD-risk factors. In fact, stearic acid (C18:0) does not increase LDL-cholesterol 
compared with carbohydrates [6] and lowers concentrations of LDL-cholesterol compared 
with other saturated fatty acids such as palmitic acid (C16:0) [7]. As palmitic acid and stearic 
acid are the most abundant saturated fatty acids in many Western diets, it is important that 
their potential differences in metabolic effects are considered when developing dietary 
guidelines for saturated fat intake. Based on the effect of stearic acid on LDL-cholesterol, the 
French Food Safety Agency (AFSSA) decided to exclude stearic acid from their dietary 
guidelines on atherogenic saturated fatty acids [8]. However, as CHD is a multifactorial 
disease, LDL-cholesterol is not the only underlying factor that contributes to the 
development of CHD. Although the effects of stearic acid compared with palmitic acid on 
LDL-cholesterol are well-known, the effects on other risk markers have been studied less 
extensively. Thus, more research is needed to draw conclusions about their effects on CHD-
risk beyond LDL-cholesterol and get a comprehensive overview of their impact on 
cardiometabolic health. Therefore, we have focused in this dissertation on the effects of the 
most commonly consumed saturated fatty acids palmitic acid and stearic acid on 
conventional and emerging cardiometabolic risk factors. Ultimately, the findings of this 
research combined with findings of other scientists may provide underlying evidence for the 
development or revision of dietary guidelines. These guidelines will help the society to 
improve diet quality and will eventually contribute to the prevention of CHD and to public 
health in general. 
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Commercial relevance 
As it is generally advised to reduce the intake of dietary saturated fatty acids, it is of great 
interest to the food industry to replace animal fats that are generally rich in saturated fatty 
acids with vegetable oils and fats rich in unsaturated fatty acids. In fact, the food industry 
nowadays heavily relies on the use of vegetable oils and fats for the production of processed 
foods, for example margarines and baked goods. However, for these food products, certain 
physical characteristics of the fats are required such as a specific melting behavior or solid 
fat content. To increase the suitability of vegetable oils and fats for the food industry, 
modification processes are used. For a long time, partial hydrogenation of vegetable oils was 
widely used. However, besides the formation of saturated fatty acids, also trans fatty acids 
were formed with partial hydrogenation. These industrially produced trans fatty acids are 
nowadays not allowed anymore as they have unfavorable effects on serum lipids and thereby 
increase the risk of developing CHD. An alternative to partial hydrogenation is 
interesterification, also known as the randomization of fats. Interesterification is a 
modification process that rearranges the fatty acids between and within triacylglycerol 
molecules resulting in new triacylglycerol species that have different physical characteristics, 
but without changing the overall fatty acid composition of the fat. Thus, in contrast to partial 
hydrogenation, no trans fatty acids are formed by interesterification [9]. However, even 
though no trans fatty acids are formed, it has been speculated that the position of the fatty 
acids within the triacylglycerol molecule determines its metabolic faith. More specifically, 
fatty acids at the sn-2 position are believed to remain attached to the glycerol backbone and 
end up in the liver where they will subsequently be incorporated into lipoproteins that enter 
the circulation. It may therefore be possible that interesterification of fats also affects 
cardiometabolic health. Vegetable fats and oils used for interesterification are often rich in 
palmitic acids and/or stearic acids. Normally, palmitic and stearic acids are mainly present at 
the outer sn-1 and sn-3 positions, but with interesterification the amount of these fatty acids 
at sn-2 increases. Thus, it is important that it is well-studied whether this position within the 
triacylglycerol molecules affects the metabolic faith of palmitic and/or stearic acids and 
thereby cardiometabolic health. As the existing literature on the effects of interesterification 
of palmitic acid- or stearic acid-rich fats is described in this dissertation, these results are also 
very relevant for the food industry. In addition, because stearic acid has a lowering effect on 
serum LDL-cholesterol compared to other saturated fatty acids, it has even been suggested 
that stearic acid-rich fats may be interesting for the production of functional foods  
 
Environmental relevance 
In the research described in this dissertation, we have predominantly studied effects of palm 
oil (rich in palmitic acids) and allanblackia oil (rich in stearic acids) on cardiometabolic health. 
These oils are both suitable for the production of interesterified fats. Palm oil, derived from 
the fruits of oil palm trees mainly found in Asia (i.e. Indonesia and Malaysia), is the most 
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commonly consumed vegetable oil. Palm oil consumption accounts for 30% of oil 
consumption worldwide. Almost half of the fatty acids in palm oil are palmitic acids. It has 
been estimated that around 75 million tonnes of palm oil will be consumed in 2019-2020 [10]. 
Although the production of palm oil is very efficient (one oil palm can produce up to 4000 
liters of oil) and a good income source for the local producers, many people are concerned 
about the use of palm oil as its increased cultivation has among others resulted in negative 
effects on plant and animal biodiversity of some tropical forests, particularly in Malaysia. A 
large number of companies and organizations therefore work together to increase 
sustainability of the production of palm oil (also known as the Round Table on Sustainable 
Palm Oil). In the Netherlands, 90% of the palm oil used nowadays is sustainable. 
Nevertheless, due to the increasing world population and consumer society, it is still 
important to also use other vegetable oils and fats when possible. Allanblackia oil is derived 
from the fruit seeds of the Allanblackia tree commonly found at tropical forests in Africa (i.e. 
Tanzania and Ghana). The physical characteristics (solid at room temperature) of allanblackia 
oil, that are mainly due to its high stearic acid content (more than half of its fatty acids), make 
this oil very suitable to use as a structuring fat by the food industry [11]. Currently, allanblackia 
seeds are mainly harvested in the wild, but this wild harvesting alone will not meet long-term 
demands. Therefore, the ‘Allanblackia Partnership’ has been founded to increase the use 
and production of allanblackia oil in a sustainable way.  
 
Translation into practice 
Given that palmitic acid and stearic acid are the most abundant saturated fatty acids in many 
Western diets and that fats rich in palmitic and/or stearic acid are often used for 
interesterification by the food industry, it is important that we thoroughly understand their 
impact on metabolic health. Of course, this research alone is not enough to reconsider 
dietary guidelines for saturated fat nor to advise the food industry on which fats to use. 
Nevertheless, the reported findings of palmitic-acid and stearic-acid intakes on a broad 
selection of conventional and emerging cardiometabolic risk markers provide a foundation 
for future studies to confirm or refute these results. The question remains how all these 
findings translate into long-term metabolic health. Therefore, future research should also 
focus on functional cardiometabolic endpoints. The findings described within this 
dissertation were presented at several (inter)national congresses. In addition, the findings 
will be published in scientific journals and thus be publicly available for scientists as well as 
for policy makers and the food industry.  
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